Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683) Chemical Structure

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 100 Publications

20 Customer Reviews

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets
HDAC [1]
(Cell-free assay)
~10 nM
In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 NGDYc|NMcW6jc3WgRZN{[Xl? MUKxJIg> MoLhSG1UVw>? NGDlfmVidnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2= MYixNVk3ODR6OR?=
Friend leukemic cell MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;NN|UxKM7:TR?= NEPueVI4OiCq MmHqSG1UVw>? MWjJR|UxRTBwOUmg{txO M2Xib|EzOTB7OUGz
K562 M335eWtqdmG|ZTDBd5NigQ>? NWDnNmRzPiCq NXjyXJR5TE2VTx?= MmfLTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN MYKxNlQyQTN6MB?=
HT1080 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDEc|BJPzJiaB?= NVzuXYZTTE2VTx?= M2jMfGlEPTB;Mj60JO69VQ>? MV[xNlI4ODF5NR?=
H1299 MUPLbY5ie2ViQYPzZZk> M{L1bVIxKG2rbh?= Mle5SG1UVw>? MUDJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgTGRCSyCnbor5cYUhf2m2aDDJR|UxKG:oIECuNVk1KM7:TR?= NFG5UIsyPDV{MUSyNi=>
H1299 NVvGZWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOxO|IhcA>? NVnhXY83TE2VTx?= MX3JR|UxRTdwMkSg{txO M1z6R|E1PTJzNEKy
HeLa NVLmW3IxU2mwYYPlJGF{e2G7 MmXMN|AhdWmw MorVTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaHnzeI9v\SCmZXHj[ZR6dGG|ZTD3bZRpKEmFNUCgc4YhOC5{ODFOwG0> Mmq0NVU3ODN7NEm=
LOX-IMVI M1OyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXRclVjPDhiaB?= NF3mZlVKSzVyPUGuN{DPxE1? MX6xOVcyPTR5MB?=
NCI-H226 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXB[4RjPDhiaB?= M{\s[mlEPTB;Mj62JO69VQ>? NFXsW4wyPTdzNUS3NC=>
RXF-631L NXvBSFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfG[oZFPDhiaB?= MV3JR|UxRTJizszN MnKxNVU4OTV2N{C=
SNB-78 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTlOFghcA>? Mn\wTWM2OD1zNjFOwG0> MVyxOVcyPTR5MB?=
St-4 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHUOFghcA>? MXfJR|UxRTVwMjFOwG0> Mn7RNVU4OTV2N{C=
ARP1 NGniUpVHfW6ldHnvckBCe3OjeR?= M4HBeVIh|ryP NWDzOFZxPiCq M2LrfGlv\HWldHnvckBw\iCSMkHXRWYyKGenbnWg[ZhxemW|c3nvci=> MWmxOFc{PDhyNh?=
CEM NHXhdpdMcW6jc3WgRZN{[Xl? M3vYS|EhcA>? NIDscnNFVVOR NX7HPVFDUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM{KM7:TR?= MWSxOlQzODB4NB?=
HCT15 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[0PEBp MWTHTVUxRTBwOEKg{txO NH7mUpgyPjd{M{KyOy=>
NCI-H23 NIm2N25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorjOFghcA>? NEnvbmlIUTVyPUCuPVIh|ryP MoLwNVY4OjN{Mke=
GM15850 MUPLbY5ie2ViQYPzZZk> NHTJbVgzNjVizszN MW[5OkBp MUPEUXNQ M33GXmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIx6e2mwZTCxOEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NWXNUFJLOTZ7MkGzOlc>
GM15850 MWLLbY5ie2ViQYPzZZk> M2rIPVIvPSEQvF2= MWK5OkBp NH3EXHBFVVOR MXjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>? NFfLT3QyPjl{MUO2Oy=>
GM15850 NHzndI1McW6jc3WgRZN{[Xl? M2PWTVIvPSEQvF2= MYO5OkBp M3;pfmROW09? NYHBVnp5UW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l MWKxOlkzOTN4Nx?=
GM15850 NEjqWJFMcW6jc3WgRZN{[Xl? MlrwNk42KM7:TR?= M{DSeVk3KGh? M{jJSGROW09? MoDqTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? NV\1SY1LOTZ7MkGzOlc>
GM15850 MX3LbY5ie2ViQYPzZZk> M2n2dVIvPSEQvF2= MkfSPVYhcA>? MoHsSG1UVw>? MoL0TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEigZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? MW[xOlkzOTN4Nx?=
GM15850 MlTMT4lv[XOnIFHzd4F6 MY[yMlUh|ryP NFrafVQ6PiCq NVTpWIN6TE2VTx?= M2\FTmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxOkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NEXyR5gyPjl{MUO2Oy=>
U937 NX;VdHUxTnWwY4Tpc44hSXO|YYm= NIDq[oQ2KM7:TR?= MkfDNlQhcA>? NV7YfIdSTE2VTx?= M2\jfWNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V? NFrwfnUyPzByNEexPC=>
H661 NXSxeIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCNFE1QCCq NV7Sb5AzUUN3ME2xJO69VQ>? M{ixXlE4OTV5MEC5
U937 MW\GeY5kfGmxbjDBd5NigQ>? NXKxW2FRPSEQvF2= MkCyNlQhcA>? MY\EUXNQ MoqwTY5kemWjc3WgbY4hcGm|dH;u[UBJOyCjY3X0fYxifGmxbh?= M1raWFE4PDR5N{Ww
U937 NVvPdHFiTnWwY4Tpc44hSXO|YYm= MVyxJO69VQ>? MYmyOEBp NVTaNGhDTE2VTx?= NU\UU3lqTW[oZXP0JI9vKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44> M1eyPFE4PDR5N{Ww
RAW264.7 MlG2SpVv[3Srb36gRZN{[Xl? MUWxNEDPxE1? MUiyOIg> NHjmb3F4[XSnch?= Mn3aTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?= MoP1NVc1Pzd3MUi=
RAW264.7 M{[3Z2Z2dmO2aX;uJGF{e2G7 NV3QbWVKOTBizszN NIftcFAzPGh? NFLHfFV4[XSnch?= MXXJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJG5QKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFEvQDhizszN NX3ZN4Y4OTd2N{e1NVg>
SC9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS2Tm9RPDhiaB?= NGDVfpRKSzVyPUCuOlA3KM7:TR?= MkK2NVc2ODd{MUm=
ST14A MnK2SpVv[3Srb36gRZN{[Xl? MlT2OUBvVQ>? MmezO|IhcA>? NFLqV2tKdmO{ZXHz[UBqdiCURWPUM25TW0ZibWLORUBmgHC{ZYPzbY9v MU[xO|U3PTl7Mx?=
ST14A MVrGeY5kfGmxbjDBd5NigQ>? NEDZWG82KG6P MkC4O|IhcA>? M1nJZmlv[3KnYYPlJIlvKEV{RkGgcXJPSSCneIDy[ZN{cW:w M{fQfVE4PTZ3OUmz
PANC1 NEHTW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xJO69VQ>? MXjJR|UxRTBwNEWg{txO NU\VTpc{OTd3OEi3OFQ>
PANC1 Mnm5SpVv[3Srb36gRZN{[Xl? MYWxJO69VQ>? M{\QcVI1KGh? MnXNTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>? M2XGRlE4PTh6N{S0
PANC1 M1LHV2Z2dmO2aX;uJGF{e2G7 NInZeFEyKM7:TR?= NYDFWWJwOjRiaB?= NGrzUHVKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW|c3nvci=> M2fJPFE4PTh6N{S0
PT45 NXq0e2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHzd25KSzVyPUSg{txO M3fyd|E4PTh6N{S0
ACHN M2X4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSyNUBp M1y5[mdKPTB;MD62OUDPxE1? MWOxO|Y3OjZyNh?=
PC3 NEOwO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnpNlEhcA>? NEftR3RIUTVyPUCuO|Eh|ryP MXyxO|Y3OjZyNh?=
A431 M3myb2N6fG:2b4jpZ{BCe3OjeR?= NXvnTm9tPzJiaB?= MlniTWM2OD12LkKg{txO MXWxO|Y6OTd4Mx?=
Cal27 M1jFWmN6fG:2b4jpZ{BCe3OjeR?= NH7i[WQ4OiCq M{TudGlEPTB;Mz6yJO69VQ>? M3;mPVE4PjlzN{[z
CCRF-CEM MkTZR5l1d3SxeHnjJGF{e2G7 MlLmO|IhcA>? M4DHSmlEPTB;MD64JO69VQ>? NWS3dZVLOTd4OUG3OlM>
EOL1 MXfDfZRwfG:6aXOgRZN{[Xl? MVy3NkBp M{nxNWlEPTB;MTFOwG0> M1n6clE4PjlzN{[z
Hec-1-A MYHDfZRwfG:6aXOgRZN{[Xl? M4\0[VczKGh? NXSySWZtUUN3ME2xJO69VQ>? MWKxO|Y6OTd4Mx?=
HeLa MYjLbY5ie2ViQYPzZZk> NGrWc|kyOCEQvF2= NYDyNJh2OzBibXnu MmO0SG1UVw>? NYe3fJpFUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFMTD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MWWxO|Y6OTd4Mx?=
RKOp21 M{W3[mN6fG:2b4jpZ{BCe3OjeR?= NHTRN4c4OiCq NFzIT|hKSzVyPUGuO|Yh|ryP M{DQ[FE4PjlzN{[z
Saos2 MlruR5l1d3SxeHnjJGF{e2G7 NGrhSFE4OiCq MVvJR|UxRTJwMzFOwG0> MmPQNVc3QTF5NkO=
SK-OV-3 NVzl[28zS3m2b4TvfIlkKEG|c3H5 M{TRSlczKGh? NHOwcHRKSzVyPUKuNkDPxE1? M1jRWVE4PjlzN{[z
U87MG NVTDdYd5S3m2b4TvfIlkKEG|c3H5 MYq3NkBp NUL6TmNVUUN3ME2xNUDPxE1? MkTTNVc3QTF5NkO=
NUGC3 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnafoY2KM7:TR?= MontNlQhcA>? M3fMTWdKPTB;Mj63PUDPxE1? MWexO|kxPDh2Mx?=
CCD1059SK M2LmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPlemRKSzVyPUSzMlUh|ryP NHW5e2cyQDJ2N{W1OC=>
HepG2 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flU2lEPTB;MD6wNFA3KM7:TR?= NESxb4QyQDJ2N{W1OC=>
HT1080 NIDER3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5[5d3UUN3ME2wMlAxOjRizszN NGW5RVYyQDJ2N{W1OC=>
SKBR3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu0U|BKSzVyPUCuPEDPxE1? NFjxOGoyQDJ2N{W1OC=>
SNB78 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlS|lGSzVyPUG2JO69VQ>? NIrHXYEyQDJ2N{W1OC=>
SQ20B MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\BTWM2OD1|IN88US=> MlnzNVgzPDd3NUS=
St4 NXXybJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLFR|UxRTVwMjFOwG0> Mlm1NVgzPDd3NUS=
MCF7 M2W1d2Z2dmO2aX;uJGF{e2G7 NVu3[pdwOTBizszN M4\DdFghcA>? NF;YbFNFVVOR NYfPWYhOUW6mdXP0bY9vKG:oIIT1ZpVtcW5iaInw[ZJi[2W2eXzheIlwdg>? MWWxPFI3QTJ{Nh?=
HEK293 NFntUVlMcW6jc3WgRZN{[Xl? NGPzZYMyKGh? NIfpWZdFVVOR M3vXWGlvcGmkaYTpc44hd2ZiSFTBR|Ehf2m2aDDJR|UxKG:oIECuNFMh|ryP NEfPOYsyQDNyOEW2Ny=>
HEK293 MlLTT4lv[XOnIFHzd4F6 M4H3V|EhcA>? MnnTSG1UVw>? M4WzUWlvcGmkaYTpc44hd2ZiSFTBR|Mhf2m2aDDJR|UxKG:oIECuNFU4KM7:TR?= NFzlSIUyQDNyOEW2Ny=>
G401 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nheFczKGh? NVfacVBmTE2VTx?= Mm\1TWM2OD1zIN88US=> NX7HZ|NSOTh|N{CzO|M>
HeLa MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KwcVczKGh? NITSRZJFVVOR NV\TfI1HUUN3ME2wMlQ3KM7:TR?= NUSzb41rOTh|N{CzO|M>
Human renal epithelial cell MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzkO|IhcA>? MnmxSG1UVw>? NWHJVIpQUUN3ME2xOEDPxE1? NX7DWIFVOTh|N{CzO|M>
U937 MoXUSpVv[3Srb36gRZN{[Xl? NH2y[Ik2KM7:TR?= MkPONlQhcA>? M{nFb2lv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25? NW\SZploOTh|OEGyN|g>
U937 NUfjZpl2TnWwY4Tpc44hSXO|YYm= NWXOUHFtPSEQvF2= Ml\VNlQhcA>? NX2xVYVtUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=> NXzzOHp7OTh|OEGyN|g>
U937 MmLvSpVv[3Srb36gRZN{[Xl? MYG1JO69VQ>? NI\KfGQzPCCq M3rZZWlv\HWldHnvckBw\iCyMkGg[ZhxemW|c3nvci=> MUSxPFM5OTJ|OB?=
U937 NE\JWpJHfW6ldHnvckBCe3OjeR?= M4XmbVUh|ryP M3zBOFI1KGh? MYLJcoR2[3Srb36gc4Yh[XCxcITvd4l{ Mk\tNVg{QDF{M{i=
U937 M{PHPGZ2dmO2aX;uJGF{e2G7 M{[w[lUh|ryP NETpXW4zPCCq MV\JcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>? MmXVNVg{QDF{M{i=
U937 Mm\XT4lv[XOnIFHzd4F6 NHvPc5A2KM7:TR?= MXyyOEBp NFrqO4JKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx NFHZbXAyQDN6MUKzPC=>
U937 NGnhXJlMcW6jc3WgRZN{[Xl? NF7GXXg2KM7:TR?= MlLoNlQhcA>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2 MUCxPFM5OTJ|OB?=
HEK-TE MX;GeY5kfGmxbjDBd5NigQ>? NYW2cYhGPSEQvF2= MUK2bC=> NIn5WZdFVVOR NUXsZXRCUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> NYrWfmZNOTh2M{SxOFQ>
HPDE6c7 M2\oNGN6fG:2b4jpZ{BCe3OjeR?= MWK1NEDPxE1? MXK3NkBp NFLBZ|RFVVOR M{HTfGlEPTB;MT6zJO69VQ>? M3fOTFE5PDl2NE[z
Human microvascular epithelial cell M4DQWmN6fG:2b4jpZ{BCe3OjeR?= MUS1NEDPxE1? M2m3VVczKGh? NUn3clB4TE2VTx?= NWj3XndbUUN3ME2xMlMh|ryP NEixRZQyQDR7NES2Ny=>
Hup T3 NV7ieIl[S3m2b4TvfIlkKEG|c3H5 NHPtXGk2OCEQvF2= MXK3Nog> M1TSeWROW09? M165Z2lEPTB;MD64JO69VQ>? MYixPFQ6PDR4Mx?=
Mia Paca2 NFXEZ|NEgXSxdH;4bYMhSXO|YYm= MYK1NEDPxE1? M2nwTVczcA>? MlrqSG1UVw>? NEKz[HRKSzVyPUGuNUDPxE1? Mnz3NVg1QTR2NkO=
Panc 04.03 MmSwR5l1d3SxeHnjJGF{e2G7 M{nGOVUxKM7:TR?= NVzSZnZmPzKq MXnEUXNQ MXPJR|UxRTFwMjFOwG0> NGrKfnYyQDR7NES2Ny=>
SU 86.86 NYXHNphkS3m2b4TvfIlkKEG|c3H5 NIGzS4Y2OCEQvF2= MnPuO|Jp MYDEUXNQ NF2xZnhKSzVyPUGuN{DPxE1? MkTzNVg1QTR2NkO=
HEK293 NXrWWFZjU2mwYYPlJGF{e2G7 MWizJIg> NXzveJM{UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1? M1fOd|E5PTV6Nk[5
HeLa MWrLbY5ie2ViQYPzZZk> NH:y[mIzKGh? NITJ[YtKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh|ryP NIi1eIgyQDV3OE[2PS=>
RAW264.7 M{XZZmZ2dmO2aX;uJGF{e2G7 MUmyJO69VQ>? NYSyNJoyOy53IHi= NX;v[mhJTE2VTx?= MWHBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN NXPVcXVrOTh4NES5Olk>
NB4 MX60PIg> M3f1Z2ROW09? MlLrTWM2OD1yLk[g{txO M3\ReVE5PzJ|M{S5
HEK293 MY\GeY5kfGmxbjDBd5NigQ>? NYi4dJdLOTBizszN MnTzNlQhcA>? MknpSG1UVw>? NGTMVlNC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ> M2PoPFE6ODJ{Nke1
HCT116 NUWyXpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfQWJpsPzKq MmXRSG1UVw>? NXy2[JFUUUN3ME2wMlMyKM7:TR?= NI\QdIYyQTB6NEK5OC=>
HeLa MmX0T4lv[XOnIFHzd4F6 NFrN[pgzKM7:TR?= NF\JSY4{OCCvaX6= NHSyPJNFVVOR MWPJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR|UxKG:oIECuNUDPxE1? NIjiOYYyQTB6NEK5OC=>
IGROV1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Pd45yPzJiaB?= NFK2WY1FVVOR NXTWZlNyUUN3ME2yMlIh|ryP Mnz4NVkxQDR{OUS=
IGROV1 M2n2O2tqdmG|ZTDBd5NigQ>? NGPEfmQ2KM7:TR?= MnnCNlQhcA>? NH23VXBFVVOR NYDZSHprUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IIC1N{Bi[2W2eXzheIlwdg>? NUjTfGg4OTlyOESyPVQ>
IGROV1 MYnLbY5ie2ViQYPzZZk> MUmxNEDPxE1? MWe0JIg> MmfBSG1UVw>? NHuydoZKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=> M4jMclE6ODh2Mkm0
IGROV1 NHXhNpRMcW6jc3WgRZN{[Xl? MYOxNEDPxE1? NELxPHc1KGh? M1To[2ROW09? M4HQNWlvcGmkaYTpc44hd2ZiSFTBR|Yh[XO|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>? NIr2bVIyQTB6NEK5OC=>
T24 M17NbmtqdmG|ZTDBd5NigQ>? NXfsSYJ7OyCq NXHNO5V4UW6mdXP0bY9vKG:oIHjpd5RwdmViSEOgZYNmfHmuYYTpc44hf2m2aDDFR|UxKG:oIECuNVIh|ryP NWGxfnBlOTlyOESzPVU>
T24 NGrOSJVMcW6jc3WgRZN{[Xl? NXP2bodmOyCq MYTJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1? M4mxTlE6ODh2M{m1
HeLa M{H3UWtqdmG|ZTDBd5NigQ>? NUKzbY5POTVibXnu MV;EUXNQ M2G5TmlvcGmkaYTpc44hd2ZiSFTBR|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0> NXXDc4hiOTlyOUO4PFQ>
HeLa MlnUT4lv[XOnIFHzd4F6 M3u1SlE2KG2rbh?= MlHpSG1UVw>? MnPNTY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2= NHfUZWcyQTB7M{i4OC=>
NCI-H69 MkLzR5l1d3SxeHnjJGF{e2G7 M{XGV|czKGh? MlP2SG1UVw>? MXrJR|UxRTJwME[g{txO Mk\vNVkxQTN6OES=
SKMES1 MWTDfZRwfG:6aXOgRZN{[Xl? NIO4d5o4OiCq NXHmbZBbTE2VTx?= M2DtcmlEPTB;Mj60NkDPxE1? NXrHdG9jOTlyOUO4PFQ>
S2 MoDvT4lv[XOnIFHzd4F6 M4XTb|AvOS1zMDFOwG0> MWCxJIg> M1mwd2lvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO NX3H[oFnOTl|MUe0OVA>
SHSY5Y NWDLTY54U2mwYYPlJGF{e2G7 MmS4NVAh|ryP NFP4RnA1QCCq NF\JOoZFVVOR NVfJNpZLUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlUh|ryP M2nEeFE6OzR2MUe1
SHSY5Y NXzaWpo4S3m2b4TvfIlkKEG|c3H5 NETvPXYyOCEQvF2= Mk\3OFghcA>? NUDvUplQTE2VTx?= MVLJR|UxRTJizszN Mlf0NVk{PDRzN{W=
DMS114 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;2OWo1QCCq MnjmS2k2OD1{Lkmg{txO NELoeGEyQTRzOUKwOS=>
HBC5 NITDUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTld2pZPDhiaB?= NIHDTYdIUTVyPUG3JO69VQ>? NHK1bHYyQTRzOUKwOS=>
SNB78 NWrmcIFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe0PEBp NGfEd5lIUTVyPUG2JO69VQ>? MXWxPVQyQTJyNR?=
HeLa NHWxeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp NHXHOWJFVVOR NGHTd2hKSzVyPUCuOFYh|ryP NVW2R4dROTl2NEG4OFY>
BHK M3;CcWtqdmG|ZTDBd5NigQ>? M3vDVVUh|ryP MorMNlQhcA>? NWTLTJVtTE2VTx?= NWDoVmZqUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5? MX2xPVk3Pjd6OR?=
CFBE41o- MlzBT4lv[XOnIFHzd4F6 M3yzelUh|ryP M1LQN|ghcA>? MkDFSG1UVw>? M{fvcmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEO= NFjzbGMyQTl4Nke4PS=>
CFBE41o- M{DvVWtqdmG|ZTDBd5NigQ>? M1e2fVUh|ryP M4LMZ|QhcA>? Ml;tSG1UVw>? MoLYTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWu MYexPVk3Pjd6OR?=
CFBE41o- NWfJb|RCU2mwYYPlJGF{e2G7 M1;hTlEh|ryP MVSxJIg> Mn\KSG1UVw>? M{nMfmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDDSnRTKHC{b4TlbY4hdGW4ZXy= MmjQNVk6PjZ5OEm=
Primary bronchial epithelial cell NGDEOFNMcW6jc3WgRZN{[Xl? MoXKNUDPxE1? MXGyOEBp M4PDfmROW09? MknHTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v NVXCSFN7OTl7Nk[3PFk>
CFBE41o- MXnLbY5ie2ViQYPzZZk> NF\6SIwyKM7:TR?= NF6wTmw2KGSjeYO= NVrq[|l2TE2VTx?= M{jI[WlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYrheIlwdiCxZjDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv NV[zNWc4OTl7Nk[3PFk>
CFBE41o- NFvTTWtMcW6jc3WgRZN{[Xl? NUjRXGhWOSEQvF2= NIDPe2YzPCCq NVjX[mUyTE2VTx?= M2rHZ2lvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?= MVuxPVk3Pjd6OR?=
CFBE41o- MULLbY5ie2ViQYPzZZk> NXT1bGlkPSEQvF2= Ml[2NlQhcA>? NYC2ZnlRTE2VTx?= NEC4UItKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS|IHfsfYNw\m:{bR?= Ml6wNVk6PjZ5OEm=
CFBE41o- MmHKT4lv[XOnIFHzd4F6 MWS1JO69VQ>? MYOyOEBp MWLEUXNQ MmLsTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrdImgc4YhTmSnbIThOVA5KEOIVGKgdJJwfGWrbh?= MV6xPVk3Pjd6OR?=
CFBE41o- NGDMPJJMcW6jc3WgRZN{[Xl? NETvXW82KM7:TR?= NHnkZ2wzPCCq NVvpTlBHTE2VTx?= NUnzR4xsUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju MlfBNVk6PjZ5OEm=
Primary bronchial epithelial cell MVTLbY5ie2ViQYPzZZk> Mn3zOUDPxE1? NX3UTWJQOjRiaB?= NF75W4VFVVOR M{LadWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v M3v0U|E6QTZ4N{i5
Primary bronchial epithelial cell NVnYRmNFU2mwYYPlJGF{e2G7 Moi5NUDPxE1? M4jMSlk3KGh? NGKy[ZhFVVOR M4LhRmlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd4hwenRiY3nyZ5VqfCCldYLy[Y51ew>? M1Ttb|E6QTZ4N{i5
BxPC3 M2nZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp MXPJR|UxRTJwNzFOwG0> Ml32NlAyPDN5N{i=
CAL27 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3NkBp NGj4OVZKSzVyPUOuO|Ih|ryP NHvNXHozODF2M{e3PC=>
Capan1 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp NFrjUWlKSzVyPUeuN{DPxE1? MlO2NlAyPDN5N{i=
HCC827 NUT4N29LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;6XlJUPzJiaB?= MnP3TWM2OD1zLkig{txO M2G3WlIxOTR|N{e4
LNCAP M2jG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zvWlczKGh? MVHJR|UxRTBwNUig{txO NHPWW5gzODF2M{e3PC=>
NCI-H2122 M12ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsO|IhcA>? NX;1Z5dKUUN3ME23MlUh|ryP NFrEPHEzODF2M{e3PC=>
NCI-H358 NFfQR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6[Hk4OiCq MlnaTWM2OD1{LkWg{txO MVKyNFE1Ozd5OB?=
SCC15 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7TO|IhcA>? MnfoTWM2OD1{LkS5JO69VQ>? NXqyPJpuOjBzNEO3O|g>
SCC25 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDTWpdKPzJiaB?= NVj3Wm5uUUN3ME2xMlk{KM7:TR?= M4DsVFIxOTR|N{e4
SKHEP1 NXj1fpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV63NkBp Ml\3TWM2OD1|LkS2JO69VQ>? MkDZNlAyPDN5N{i=
BJ M2G4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xNFAh|ryP MYS0PEBp NVTpWJdnTE2VTx?= NV\We5g3T3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0> MWqyNFE1Ozh2MB?=
MUF NHPmbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH6NVAxKM7:TR?= M4TMWVQ5KGh? NEL0WHFFVVOR MnrkS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2= NUDLc2dIOjBzNEO4OFA>
Caco-2 M4HWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK0NVAxKM7:TR?= MU[0PIg> MYrEUXNQ MmHKTWM2OD16LkGg{txO M{jE[VIxOTR|OESw
Caco-2 NXqwbW0{U2mwYYPlJGF{e2G7 MkiwOUDPxE1? MoLsOEBp M1\qVWROW09? MnjBTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvckBKSzVyIH;mJFAvODN5IN88US=> NWXTOo06OjBzNEO4OFA>
Caco-2 MWjLbY5ie2ViQYPzZZk> MnOyNE4{OTZibl2geI8hOzFwNjFOwG0> NXXzXGRnPCCq MX7EUXNQ M2\P[2V5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTD3bZRpKEmFNUCgc4YhOC5zMUmg{txO Ml\QNlAyPDN6NEC=
Caco-2 NIfk[ZVMcW6jc3WgRZN{[Xl? NIi2XHkxNjNzNjDuUUB1dyB|MT62JO69VQ>? M1joWFQhcA>? NYPqW3JyTE2VTx?= MUfFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzNid3n0bEBKSzVyIH;mJFAvOTR5IN88US=> NVrJVGc1OjBzNEO4OFA>
Caco-2 Mnj3T4lv[XOnIFHzd4F6 M37BdFYvOzJibl2geI8hPjN{IN88US=> M1z2VlQhcA>? NF;GOYtFVVOR Ml\oSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN3IIfpeIghUUN3MDDv[kAyOi54IN88US=> NXH6bFNZOjBzNEO4OFA>
Caco-2 MmXHT4lv[XOnIFHzd4F6 NX3HTVFqPi5|MjDuUUB1dyB4M{Kg{txO M4\rWFQhcA>? NIeyTHdFVVOR MX3FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?= NVSzc4txOjBzNEO4OFA>
Caco-2 NYPiV4ZPU2mwYYPlJGF{e2G7 M4nSdlAvOzF4IH7NJJRwKDNzLk[g{txO MkH4OEBp M1nDOmROW09? MXLFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ? M1jmUFIxOTR|OESw
HepG2 NIfoZ3BMcW6jc3WgRZN{[Xl? MVq1JO69VQ>? NF3mbJY3cA>? MoLKSG1UVw>? M4PiU2lv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44> MknqNlAyPDN6NEC=
HepG2 M{XBXWtqdmG|ZTDBd5NigQ>? NUjDcW4{PSEQvF2= NIX4e5I3cA>? NWP5Vm8{TE2VTx?= MXLJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25? MnfGNlAyPDN6NEC=
HepG2 M1LXNmtqdmG|ZTDBd5NigQ>? MWi1JO69VQ>? Mm\4Oog> NV\2NohDTE2VTx?= NYPTcYlIUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=> Moj4NlAyPDN6NEC=
HepG2 MkW3T4lv[XOnIFHzd4F6 NFHadIc2KM7:TR?= M4jOTFZp M17r[2ROW09? M1jHWWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36= MlHNNlAyPDN6NEC=
COLO205 M3HHOmtqdmG|ZTDBd5NigQ>? NUjLVVdNOTBizszN NHXES44zPCCq NELKO2FFVVOR M2rqVGlvcGmkaYTpc44hd2ZiSFTBR|Eh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25id3n0bEBKSzVyIH;mJFIvOiEQvF2= M4jMPFIxPDVzM{e4
SCC4 Moj5T4lv[XOnIFHzd4F6 M{\kOlEh|ryP M1W4cVI1cA>? MYrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5idIXieYxqdiCjY3X0fYxifGmxbh?= MXuyNFQ2OjJ{NR?=
SCC4 MmfUT4lv[XOnIFHzd4F6 NFLiS3IyKM7:TR?= NHrRTJIzPGh? MYrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCjY3X0fYxifGmxbh?= MYOyNFQ2OjJ{NR?=
SCC4 Mlj4SpVv[3Srb36gRZN{[Xl? NVvBcllxOSEQvF2= MkXiOUBucW5? NHTE[G9C\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO|aX;u M4XJUVIxPDV{MkK1
NB4 MYHGeY5kfGmxbjDBd5NigQ>? M{D3cVUh|ryP NHqxXWkzPCCq NUjiSmI{TE2VTx?= NUXtNoV4S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNkfW23bHH0bY9vKGG2IIDy[U1IOSCyaHHz[S=> M3iy[|IxPDlzNESw
NB4 NWDwUpg2U2mwYYPlJGF{e2G7 MUK1JO69VQ>? NXPIZ5BHOjRiaB?= M3f0R2ROW09? MmTyTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHHj[ZR6dGG2ZTD0eYJ2dGmwIHzleoVt M1LsZVIxPDlzNESw
NB4 MWLGeY5kfGmxbjDBd5NigQ>? MYW1JO69VQ>? MWqyOEBp NYH0T5ltTE2VTx?= NULiWIEzUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v MorQNlA1QTF2NEC=
NB4 NXHROJVCU2mwYYPlJGF{e2G7 MmrEOUDPxE1? MonLNlQhcA>? Mlu4SG1UVw>? NF6zSIRKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>? M{mwUVIxPDlzNESw
NUGC3 NEPMZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX3XWdIUTVyPUKuPVQh|ryP NFW0dZEzODh3MEm3NS=>
A549 NY\Y[2xETnWwY4Tpc44hSXO|YYm= MVy1JO69VQ>? M1nuW|MhcA>? MWnEUXNQ MVzJcoR2[3Srb36gc4Yh[XW2b4DoZYd6KGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVEN|SVm= NH34fFkzODh3NUKwPC=>
HUT78 M2XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKzOVg4OiCq NFHsV4dFVVOR NX[weFFWT0l3ME2wMlMh|ryP NIHWOYUzODh6NEKwPC=>
U937 NX30TZpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6yZoo4OiCq M{XYR2ROW09? MU\HTVUxRTBwM{mg{txO NX\HcWd2OjB6OESyNFg>
A431 M1zXS2N6fG:2b4jpZ{BCe3OjeR?= M2\2ZVczKGh? M3PydGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?= M2\3eFIyODhyNkK5
A549 M2fv[GN6fG:2b4jpZ{BCe3OjeR?= NWTtcnF1PzJiaB?= NWjEUG9pS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN NYHJNIRoOjFyOEC2Nlk>
CAL27 NGn2[HBEgXSxdH;4bYMhSXO|YYm= MkOwO|IhcA>? NVjGTIk6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=> M4fTdlIyODhyNkK5
HeLa NYPBenhNS3m2b4TvfIlkKEG|c3H5 NHzJbFM4OiCq NY\TS|kyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjVizszN MYWyNVA5ODZ{OR?=
Sf21 NG\wTFJMcW6jc3WgRZN{[Xl? M2rZbFMhcA>? M1XaVGlvcGmkaYTpc44hd2ZiRnzh[{B1[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzhiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjJizszN MoPyNlExQDB4Mkm=
SKBR3 NGHzSGNEgXSxdH;4bYMhSXO|YYm= MYe3NkBp NHXlb2lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjZizszN MmTuNlExQDB4Mkm=
SKOV3 Mn;nR5l1d3SxeHnjJGF{e2G7 MVq3NkBp NULvTXRQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=> M2HqcFIyODhyNkK5
COR-L23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonRNVAh|ryP NX3X[JFZPzJiaB?= MYXEUXNQ NIDr[YhIUTVyPUGuNUDPxE1? NVHsS4VrOjFyOEC2OFc>
DU145 NVTzTGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBeWZwOTBizszN NX3wTY5xPzJiaB?= NEHYN5ZFVVOR NVzSZXZwT0l3ME2xMlA2KM7:TR?= NFvlWoIzOTB6ME[0Oy=>
LoVo MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHVPJMyOCEQvF2= NUDKSIs4PzJiaB?= MVzEUXNQ MmDpS2k2OD1zLkeg{txO Ml;yNlExQDB4NEe=
MCR5-SV2 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHCd5pnOTBizszN MWK3NkBp M3jPXmROW09? NXXCRo4yT0l3ME2yMlEh|ryP MV6yNVA5ODZ2Nx?=
HCT116 M3rCS2tqdmG|ZTDBd5NigQ>? NF3rcGI{OCEQvF2= NUPUdoZOOzBiaB?= NIjySIhFVVOR NGj0OIVKdmirYnn0bY9vKG:oIFjERWM3KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u NXvYeWVKOjFyOEC2OFc>
HCT116 NYHwb4J5U2mwYYPlJGF{e2G7 MWizNEDPxE1? NGfRU2g{OCCq MX;EUXNQ NUjkVpJIUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u NYLyTGk2OjFyOEC2OFc>
U937 MXrLbY5ie2ViQYPzZZk> MUi1JO69VQ>? MUSyOEBp MlvTSG1UVw>? NXznc2VxUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m= M3\6UVIyOjl{NEmy
U937 NFfLT5dMcW6jc3WgRZN{[Xl? MWS1JO69VQ>? M1myW|I1KGh? NVLX[lJJTE2VTx?= Ml3HTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzF6 MVqyNVI6OjR7Mh?=
U937 NIW2UGdMcW6jc3WgRZN{[Xl? M1yxUFUh|ryP NET2TGwzPCCq MoXPSG1UVw>? MX\Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>? NI\WR|gzOTJ7MkS5Ni=>
U937 NF\SWHRMcW6jc3WgRZN{[Xl? M{nw[|Uh|ryP NUXUeIxWOTVibXnu Ml;JSG1UVw>? MWTJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=> M1TkcVIyOjl{NEmy
A2780 NIi2WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO5OkBp MV\EUXNQ M2e1S2lEPTB;MT62NkDPxE1? MXKyNVY{PDR|MB?=
COLO205 M3XoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qweVk3KGh? MorCSG1UVw>? MonxTWM2OD1{LkGyJO69VQ>? NWLNRpJyOjF4M{S0N|A>
Hep3B NIj0[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu0PEBp NIPCPWdFVVOR Mof4S2k2OD1zLkKxJO69VQ>? M1HLd|IyPzF{MUS2
GM11272 Mk\3SpVv[3Srb36gRZN{[Xl? NWPteZgyOTByIH7N NXrUTlZyPzJiaB?= MX\EUXNQ NX3ZTFh2WmWjY4TpeoF1cW:wIH;mJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:wIHH0JFExKHSxIEGwNEBvVQ>? NH32WVQzOTh2MEexOi=>
CFBE41o MmHaT4lv[XOnIFHzd4F6 MlnoOUDPxE1? MkDJSG1UVw>? MXjEc5dvKHKnZ4XsZZRqd25ib3[gTGRCSzdiYYSgNE4zKHSxIEWgeW0> MmXINlE6QDR7NUi=
CFBE41o MYrGeY5kfGmxbjDBd5NigQ>? M4HBTlEh|ryP Mm\xNlQhcA>? MYjEUXNQ M4\MbXJme3SxcnH0bY9vKG:oIFPGWHIh\GWudHHGOVA5KG23dHHueEB1emGoZnnjb4lv\yC2bzDj[YxtKHO3cn\hZ4Uh[XNiZ3z5Z49nd3Kvcx?= NYnW[2J7OjF7OES5OVg>
DU145 NFrwbJVMcW6jc3WgRZN{[Xl? MofHNk42KM7:TR?= MlvFNlQhcA>? NIfTOJVFVVOR MWDJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO|aX;u M1nh[VIzOjZyMU[2
DU145 MYLLbY5ie2ViQYPzZZk> MX21JO69VQ>? NVjkOJdEOjRiaB?= NHToZYdFVVOR NYS0WmJSUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHjpd5RwdmViSESgZYNmfHmuYYTpc44> NWnNcIhWOjJ{NkCxOlY>
DU145 NHz6XnZMcW6jc3WgRZN{[Xl? MkjKOUDPxE1? M{jkS|I1KGh? NX62[lhOTE2VTx?= NX7rNYRiUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?= NH22TnEzOjJ4MEG2Oi=>
786-0 NG\RVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3JOk4zKM7:TR?= NEX0Uow4OiCq M1r6NWROW09? NEfDN2tIUTVyPUOuNkDPxE1? MojxNlI1OzV4Nkm=
A498 NWO2W2VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe2MlIh|ryP MoeyO|IhcA>? MYfEUXNQ NWW3RoR1T0l3ME2xMlYh|ryP NVLJZ|R6OjJ2M{W2Olk>
A549/ATCC NGC4XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluwOk4zKM7:TR?= NHrOZ5Q4OiCq MUnEUXNQ M{fuSmdKPTB;MT62JO69VQ>? Mm\GNlI1OzV4Nkm=
ACHN M{jk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK2MlIh|ryP MXi3NkBp M1rHdWROW09? M2H4PWdKPTB;MT6zJO69VQ>? MVmyNlQ{PTZ4OR?=
BT549 NWf2NHQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyOk4zKM7:TR?= Mk\kO|IhcA>? NFTF[3dFVVOR MX7HTVUxRTFwMzFOwG0> MWKyNlQ{PTZ4OR?=
EKVX NIPINFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvTSJo4Pi5{IN88US=> Mm\yO|IhcA>? Mk\2SG1UVw>? MV\HTVUxRTFwMzFOwG0> MVeyNlQ{PTZ4OR?=
HCT15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\RRVQ3NjJizszN NIP2No44OiCq MlruSG1UVw>? NGTXeIpIUTVyPUKuOUDPxE1? MVWyNlQ{PTZ4OR?=
HOP92 NFv2ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PtNFYvOiEQvF2= NWPOV3dGPzJiaB?= NITYPGJFVVOR NH;SN3NIUTVyPUSg{txO NIKwdpIzOjR|NU[2PS=>
IGROV1 M17sRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf5PWdrPi5{IN88US=> MoC1O|IhcA>? NEHufHFFVVOR MU\HTVUxRTFwMzFOwG0> MnTvNlI1OzV4Nkm=
LOXIMVI NVLYSpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn2R25uPi5{IN88US=> MXi3NkBp MUfEUXNQ Mo\sS2k2OD1zIN88US=> MVeyNlQ{PTZ4OR?=
M14 M{jINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSyTodQPi5{IN88US=> NF7jelQ4OiCq NVrxVZBqTE2VTx?= NVz1[HFCT0l3ME2xMlMh|ryP NHnwcFYzOjR|NU[2PS=>
MALME-3M M4e5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf6Noo3NjJizszN Mn;GO|IhcA>? NUL0Wmk5TE2VTx?= M{HITmdKPTB;MD6zNkDPxE1? Ml\kNlI1OzV4Nkm=
MCF10A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe2MlIh|ryP M1;IXVQ5KGh? Ml\USG1UVw>? NH;2[GhIUTVyPUmuOkDPxE1? MVuyNlQ{PTZ4OR?=
MDA-MB-435 NGnWbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zclYvOiEQvF2= MkTYO|IhcA>? MmPPSG1UVw>? MmHqS2k2OD1yLkWg{txO NH7VPI4zOjR|NU[2PS=>
MDA-MB-468 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rxVVYvOiEQvF2= NY\oOJBCPzJiaB?= M{TqV2ROW09? MXrHTVUxRTBwNkOg{txO NGLURpgzOjR|NU[2PS=>
MOLT4 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4OYw3NjJizszN NYT2NFNPPzJiaB?= MYHEUXNQ M2mzXWdKPTB;MD60JO69VQ>? NEnVWoczOjR|NU[2PS=>
NCI-ADR-RES NX74UXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfV[mY3NjJizszN NYOxO2pNPzJiaB?= NIPCS45FVVOR NF\1RY9IUTVyPUCuNVYh|ryP MmTCNlI1OzV4Nkm=
NCI-H23 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTvSmRPPi5{IN88US=> MWK3NkBp NFHVSJhFVVOR MV3HTVUxRTFizszN MVuyNlQ{PTZ4OR?=
NCI-H322M NIrFc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe2MlIh|ryP M{nwVFczKGh? MkTxSG1UVw>? NY\iN|c5T0l3ME2wMlc6KM7:TR?= M{LhUFIzPDN3Nk[5
NCI-H460 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDwUYhbPi5{IN88US=> MYK3NkBp NFLwS2ZFVVOR MonoS2k2OD1yLke5JO69VQ>? NWj1VJRTOjJ2M{W2Olk>
NCI-H522 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXROk4zKM7:TR?= NIHHO|Q4OiCq M{fvTGROW09? MlroS2k2OD1yLkWg{txO MmXnNlI1OzV4Nkm=
OVCAR3 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qTYY3NjJizszN M{DqbVczKGh? MYTEUXNQ MVPHTVUxRTFwMzFOwG0> NHnD[YczOjR|NU[2PS=>
OVCAR4 M1Pxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnDO5BJPi5{IN88US=> MWi3NkBp MXzEUXNQ MXfHTVUxRTRizszN MmPENlI1OzV4Nkm=
OVCAR5 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P0SVYvOiEQvF2= NFnNR5A4OiCq MW\EUXNQ M{\E[mdKPTB;MD63PUDPxE1? M2HZb|IzPDN3Nk[5
OVCAR8 NUHTcYltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnpZZE3NjJizszN MYO3NkBp MYrEUXNQ NGDMR3VIUTVyPUCuOUDPxE1? M4XuRVIzPDN3Nk[5
RXF393 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Je5A3NjJizszN MVm3NkBp MV;EUXNQ Mme4S2k2OD1zLkOg{txO NGmxc5kzOjR|NU[2PS=>
SF268 M4TJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW2MlIh|ryP MmHTO|IhcA>? NUPsNHV{TE2VTx?= NES1fm9IUTVyPUGuOkDPxE1? MUmyNlQ{PTZ4OR?=
SF295 NWHRSoVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe2dWpNPi5{IN88US=> MnH6O|IhcA>? M4rhWGROW09? M13PTWdKPTB;MT62JO69VQ>? MWqyNlQ{PTZ4OR?=
SF539 NVf3[Yw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\aeGFDPi5{IN88US=> MWm3NkBp NIq1PJRFVVOR M1zLU2dKPTB;MjFOwG0> NET5[G8zOjR|NU[2PS=>
SK-MEL-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX25XnNYPi5{IN88US=> M4S4[|czKGh? MlLQSG1UVw>? NEWxZmRIUTVyPUGuN{DPxE1? M1vaflIzPDN3Nk[5
SK-MEL-28 NHLkWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TZUlYvOiEQvF2= NH7pZno4OiCq NHPqRXpFVVOR M{Pnd2dKPTB;MTFOwG0> NYDSO5A{OjJ2M{W2Olk>
SK-MEL-5 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqwbI43NjJizszN M2TFdFczKGh? MkS2SG1UVw>? M2TreGdKPTB;MD62N{DPxE1? MUeyNlQ{PTZ4OR?=
SKOV3 NWj3NpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kOk4zKM7:TR?= NEHySnk4OiCq NVP1WY03TE2VTx?= NELm[pBIUTVyPUGg{txO MViyNlQ{PTZ4OR?=
SN12C NYXve|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK2MlIh|ryP M{H4SlczKGh? NYL3PFdrTE2VTx?= NXnrSIZWT0l3ME2yJO69VQ>? MmTSNlI1OzV4Nkm=
SNB19 M4fUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMOk4zKM7:TR?= NX31VXRYPzJiaB?= NXrBNYZ{TE2VTx?= Mo[wS2k2OD1yLk[zJO69VQ>? NHzRO2wzOjR|NU[2PS=>
SNB75 NYHVcmVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLJRW43NjJizszN Mn6yO|IhcA>? NHToXoVFVVOR M2TmZ2dKPTB;MD63PUDPxE1? M{XlOVIzPDN3Nk[5
SR NVSyXndqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCRXE3NjJizszN NHzTOlA4OiCq Ml;oSG1UVw>? M13SU2dKPTB;MD60JO69VQ>? Mn;GNlI1OzV4Nkm=
T47D NVvMW4h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr1RWk3NjJizszN NHXJOmc4OiCq NH7MW|hFVVOR NXL5UmVwT0l3ME2wMlUh|ryP MWSyNlQ{PTZ4OR?=
TK10 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ZOk4zKM7:TR?= MUC3NkBp M1fHW2ROW09? NW[0NIhnT0l3ME2wMlY{KM7:TR?= MlHJNlI1OzV4Nkm=
UACC257 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXVbGs3NjJizszN MYi3NkBp MYfEUXNQ NVjocZVnT0l3ME2wMlUh|ryP MlntNlI1OzV4Nkm=
UACC62 NYHKZWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHyfnNPPi5{IN88US=> M1S5RlczKGh? MYLEUXNQ M1u4PGdKPTB;MD60JO69VQ>? MUiyNlQ{PTZ4OR?=
UO31 M33uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG2MlIh|ryP NWnlUYh6PzJiaB?= NX7oO|MzTE2VTx?= MVvHTVUxRTBwNTFOwG0> MmXzNlI1OzV4Nkm=
Hep3B MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[x[ox1PDhiaB?= MUTEUXNQ M3jlNGdKPTB;MD62PUDPxE1? MmezNlI1Ozl6NkO=
BE(2)-C NWKxe21yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHYZpZEPzJiaB?= MnrRSG1UVw>? MYLJR|cxRTJizszN Ml3kNlI6OzJ|MU[=
Bel7402 NX\yfmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\pd|NXPzJiaB?= NXHKelFiTE2VTx?= MlvXS2k6OD1zNzFOwG0> MkHNNlMxPjF|N{[=
Bel7404 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnaOoM4OiCq NWC4PVV5TE2VTx?= NF:3W5lIUTlyPUG4JO69VQ>? NFvPcnEzOzB4MUO3Oi=>
BGC823 NXXCfY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp M{fFe2ROW09? MlKwS2k6OD15LkWg{txO NVXNV5FKOjNyNkGzO|Y>
MGC803 NVWwS2VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHEPGM3PzJiaB?= MVfEUXNQ NUiwdXV4T0l7ME2xNE45KM7:TR?= MmqwNlMxPjF|N{[=
SGC7901 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPyc|VvPzJiaB?= NUjORXpFTE2VTx?= MW\HTVkxRTlwNDFOwG0> NUfUS3dSOjNyNkGzO|Y>
SKHEP1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHkO|IhcA>? NIfu[WFFVVOR M4PGV2dKQTB;MUeg{txO Mnf4NlMxPjF|N{[=
SMMC7721 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYntW2Z{PzJiaB?= MXPEUXNQ MXnHTVkxRTJyIN88US=> NYGye2pGOjNyNkGzO|Y>
NUGC3 NGfGb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi5co9HOTBizszN MkX5S2k:Oi57NDFOwG0> M3e2NVI{OTZ|M{Oy
A2780 CisR NHvRN4tMcW6jc3WgRZN{[Xl? Mni2NVghcA>? NHmxeWVKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOFQh|ryP MUmyN|I2OjZyMx?=
CAL27 sens M1\sdWtqdmG|ZTDBd5NigQ>? NHHDdYsyQCCq NYmzdJFoUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?= NXrC[GxvOjN{NUK2NFM>
CAL27 CisR MUnLbY5ie2ViQYPzZZk> M{jsVVE5KGh? MYXJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO NX\RXHJDOjN{NUK2NFM>
KYSE-510 CisR M3rERmtqdmG|ZTDBd5NigQ>? M4Xkc|E5KGh? MVvJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO M2XNS|I{OjV{NkCz
KYSE-510 sens NVXNRYlYU2mwYYPlJGF{e2G7 NISzWo0yQCCq MoPSTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO MlvkNlMzPTJ4MEO=
MDA-MB-231 sens MVjLbY5ie2ViQYPzZZk> MljDNVghcA>? MWDJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO Mn;FNlMzPTJ4MEO=
MDA-MB-231 CisR NWfGSmk3U2mwYYPlJGF{e2G7 MoqzNVghcA>? M3W5eWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1? NVjIZXhDOjN{NUK2NFM>
ES2 M2D4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHmOFghcA>? NYfYSnhRTE2VTx?= MX7JR|UxRTF{Lkeg{txO NWfh[mFtOjN2OUO0OFk>
MDA-MB-231 MkTQT4lv[XOnIFHzd4F6 MXGxNEDPxE1? MYSzNEBucW5? NVrRUHBNTE2VTx?= MUDJcohq[mm2aX;uJI9nKEiGQVOyZS=> MkTzNlM1QTN2NEm=
MDA-MB-231 NVrNUJA1U2mwYYPlJGF{e2G7 NVnqN2RmOSEQvF2= NFS5dIczPCCq M4\ZVWROW09? M1LLeGlvcGmkaYTpc44hd2ZiSFTBR|Yh[XO|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy|IH;mJJR2[nWuaX6= M2XBS|I{PDl|NES5
HS68 M1P6NGN6fG:2b4jpZ{BCe3OjeR?= NELiPG0yOCEQvF2= Mnv1O|IhcA>? NEDvTmlFVVOR NGrRNFVKSzVyPUSuOkDPxE1? MVWyN|U4ODV2Mh?=
MEF Mlv6R5l1d3SxeHnjJGF{e2G7 M1f2ZVExKM7:TR?= NULCc2xYPzJiaB?= M2LX[mROW09? MmW4TWM2OD12LkSg{txO M{P0bFI{PTdyNUSy
BGC823 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2xUnVFVVOR NHrUTmFIUTVyPUOuNFkh|ryP MlW3NlM3ODF5ME[=
High5 MoXwT4lv[XOnIFHzd4F6 NGLYdlYzPCCq M3rhS2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR|Yhf2m2aDDJR|UxKG:oIECuNFkh|ryP NH3ldo4zOzZyMkWyNy=>
High5 M37NTGtqdmG|ZTDBd5NigQ>? MnfBNlQhcA>? MmPPTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6xNkDPxE1? MkXiNlM3ODJ3MkO=
High5 MWfLbY5ie2ViQYPzZZk> NU\aTY9UOjRiaB?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>? M2HsTFI{PjB{NUKz
A549 NULMOWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLEUXNQ MX;JR|UxRTFwMEe5JO69VQ>? M{m2WlI{PjR2MkGw
HCT116 NVLib3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJSG1UVw>? MnL2TWM2OD1yLke1O{DPxE1? NXXJTlVGOjN4NESyNVA>
K562 M2Ppcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvlNpdFVVOR MmXuTWM2OD1yLk[0OUDPxE1? MnjqNlM3PDR{MUC=
GBC-SD MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny3OUDPxE1? MmLKO|IhcA>? NFqzc3pFVVOR NVvxNmVqUUN3ME2xOE45KM7:TR?= NGXnVpYzOzdyN{K2NC=>
HGC27 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn4OUDPxE1? Mn\uO|IhcA>? MUfEUXNQ MoizTWM2OD13LkSg{txO MmX0NlM4ODd{NkC=
HL60 MlfMT4lv[XOnIFHzd4F6 MmrzOUDPxE1? M33uZVI1KGh? NXTFVJdHTE2VTx?= MXjJcohq[mm2aX;uJI9nKEiGQVO= M3TQb|I{PzB5Mk[w
Vero NULTWGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDNO|IhcA>? MoDJSG1UVw>? MkmyTWM2OD1yLkmg{txO MV6yN|c5PjR3Mh?=
NCI60 M{TMXGN6fG:2b4jpZ{BCe3OjeR?= NIf4b2Q1QCCq M{\zXGROW09? MkH6S2k:OC53MzFOwG0> MYOyOFAyPTN{Nx?=
SW620 MX\DfZRwfG:6aXOgRZN{[Xl? MYq0PEBp MoHoSG1UVw>? M3rueGdKRTBwNUSg{txO M1yyNVI1ODF3M{K3
U251 MlXpR5l1d3SxeHnjJGF{e2G7 MX:0PEBp M2TxbWROW09? MWnHTV0yNjV|IN88US=> MmfnNlQxOTV|Mke=
KM12 NUfBVY1tS3m2b4TvfIlkKEG|c3H5 M1v4TVQ5KGh? NV7WemZoTE2VTx?= NIm1S|RIUT1zLki4JO69VQ>? NV\NSlB{OjRyMUWzNlc>
Hs578T MXTDfZRwfG:6aXOgRZN{[Xl? NXjGbotHPDhiaB?= M1PGd2ROW09? M1nxfWdKRTRwOEOg{txO NELBfYQzPDBzNUOyOy=>
MDA-MB-231 NXXOPXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPKOZg1QCCq M4m4[mlEPTB;MD6xOkDPxE1? NF7m[YQzPDB7NUCxOi=>
MCF7 NEHNe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqfJhGPDhiaB?= MUjHTV0xNjR3IN88US=> NHH5d|UzPDFzOUW1OS=>
MDA-MB-435 M2Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKVHRuPDhiaB?= NFu4dZVIUT1yLki4JO69VQ>? MYeyOFEyQTV3NR?=
AsPC1 M2DNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrPcoRoOzBizszN NVnW[FE6PDhiaB?= MXXEUXNQ NUOzZVU2UUN3ME2zMlY3KM7:TR?= MVOyOFE5PTN5OB?=
Jurkat E6.1 NXLzfIE5U2mwYYPlJGF{e2G7 MoTVNkBp NEfRU25FVVOR MlvxTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1? NXPwU2RvOjR{NkG4OlI>
KG1 M3nKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknzOFghcA>? M3\1bGlEPTB;MT6xOUDPxE1? NXfKSIFVOjR3MkWwNFM>
HEL NVf4b5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nU[FQ5KGh? NVvXXXAzTE2VTx?= M3jLSWlEPTB;MD60PUDPxE1? MUeyOFY6PDB3NR?=
HSC3 NFnMNnNEgXSxdH;4bYMhSXO|YYm= NGLIOW4yOiCq NW\SOIFQTE2VTx?= NYSxd4ljUUN3ME2wMlcyKM7:TR?= MUOyOFc3PjV4MB?=
HT-29 MlOwR5l1d3SxeHnjJGF{e2G7 NE\u[4MyOiCq MWLEUXNQ NHT2VlhKSzVyPUCuO|Ih|ryP MVeyOFc3PjV4MB?=
KB MXHDfZRwfG:6aXOgRZN{[Xl? NWC5d|JqOTJiaB?= M3Tzb2ROW09? NVexb4c5UUN3ME2wMlc2KM7:TR?= NF7XWVgzPDd4NkW2NC=>
H460 MoT6R5l1d3SxeHnjJGF{e2G7 M1X5TFEzKGh? MWXEUXNQ NV7qbGh2UUN3ME2wMlgzKM7:TR?= MU[yOFc3PjV4MB?=
MONE1 Mn;UR5l1d3SxeHnjJGF{e2G7 MXixNkBp NXKzZ3pzTE2VTx?= MVzJR|UxRTFwMUig{txO MmDmNlQ4PjZ3NkC=
MKN45 MnP1R5l1d3SxeHnjJGF{e2G7 M1vQ[|EzKGh? M1;lWGROW09? NVPIUod{UUN3ME2xMlI2KM7:TR?= MV2yOFc3PjV4MB?=
TSGH NUHEVpNLS3m2b4TvfIlkKEG|c3H5 M{fX[FEzKGh? NHyxNXRFVVOR NF\MdllKSzVyPUKuNFkh|ryP MYSyOFc3PjV4MB?=
HL60 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrSW2prPzJiaB?= MmjnSG1UVw>? MV;HTVUxRTBwOUOg{txO NWXUVFJJOjR7MEC1NFA>
HEK293 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHLO|IhcA>? MVjEUXNQ MYLHTVUxRTF|IN88US=> M2jQVFI1QTByNUCw
Jurkat MoLRR5l1d3SxeHnjJGF{e2G7 M1HNclExOCEQvF2= MWO3NkBp M2POSGdKPTB;MD65JO69VQ>? MYWyOFkxODd2Mx?=
GM15850 MUHLbY5ie2ViQYPzZZk> MU[yMlUh|ryP MX25OkBp NUW1bGluTE2VTx?= NIjxZ3pld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJOyCueYPpcoUhOTRiYXPleJlt[XSrb36gc4YhTliQIHflcoU> Mkn3NVY6OjF|Nke=
GM15850 NXnUe2pIU2mwYYPlJGF{e2G7 NEfsS3AzNjVizszN NU\q[GM6QTZiaB?= NWHZNI1uTE2VTx?= M1TPVYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA2KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l NFnVOncyPjl{MUO2Oy=>
GM15850 NHjwcVFMcW6jc3WgRZN{[Xl? M4LTN|IvPSEQvF2= M3TNPFk3KGh? MV7EUXNQ M3e1N4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyOiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NV:2cG83OTZ7MkGzOlc>
GM15850 M4SzNWtqdmG|ZTDBd5NigQ>? NYDpNIhXOi53IN88US=> M1PNNlk3KGh? MXLEUXNQ NWnlXINt\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDliYXPleJlt[XSrb36gc4YhTliQIHflcoU> MVWxOlkzOTN4Nx?=
GM15850 M2jZ[mtqdmG|ZTDBd5NigQ>? MVyyMlUh|ryP MoTyPVYhcA>? MUHEUXNQ Ml;L[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW= M3rFdlE3QTJzM{[3
GM15850 NVrsO2YxU2mwYYPlJGF{e2G7 MXeyMlUh|ryP NHrhNoc6PiCq MkTvSG1UVw>? M4SzWoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NFHFRYoyPjl{MUO2Oy=>
GM15850 MYnGeY5kfGmxbjDBd5NigQ>? MXi1JO69VQ>? M2HCRlEzKGh? M{TXNmROW09? M2HaeohieyCwbzDl[oZm[3Rib36gSnhPKG2UTlGg[ZhxemW|c3nvci=> M3;LOVE3QTJzM{[3
U937 M4XwSmtqdmG|ZTDBd5NigQ>? M2X4O|Uh|ryP M2KxfFI1KGh? M1PCU2ROW09? MYroZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25? MXmxO|Q1Pzd3MB?=
U937 M{TKWGtqdmG|ZTDBd5NigQ>? MVexJO69VQ>? M4nCSlI1KGh? NWjSeI05TE2VTx?= Ml33bIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w MWCxO|Q1Pzd3MB?=
PANC1 NXf3PGN7TnWwY4Tpc44hSXO|YYm= NXO0eFljOSEQvF2= NX;0d|ZJOjRiaB?= Mlm0[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36= MmTRNVc2QDh5NES=
PANC1 MojvSpVv[3Srb36gRZN{[Xl? NXnPbWR4OSEQvF2= M3:2RVQ5KCCq NH\XbXFld2W|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW|c3nvci=> NWWzV3c2OTd3OEi3OFQ>
Caco-2 NHSwXGZHfW6ldHnvckBCe3OjeR?= MlTmOUDPxE1? M3KzRVI1KGh? NET5SIhFVVOR M1y5OoRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>? NELtPGkzODF2M{i0NC=>
SCC4 NGLK[5pHfW6ldHnvckBCe3OjeR?= NWntcIpxOSEQvF2= MX:xNEBucW5? M4DqdWROW09? NYnwRm1vcGG|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36= M4L5W|IxPDV{MkK1
A549 NUfoN4FvTnWwY4Tpc44hSXO|YYm= Mn3QOUDPxE1? MXmzJIg> NXXuUHdETE2VTx?= NFTZc29ld2W|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK NHfDemMzODh3NUKwPC=>
HCT116 M2\vb2tqdmG|ZTDBd5NigQ>? MnfZNE4{KM7:TR?= MUezNEBp M2XHSWROW09? M3OzVoRw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=> MV:yNVA5ODZ2Nx?=
HepG2 NIHvfW1HfW6ldHnvckBCe3OjeR?= MkDBNVAh|ryP M2LvSFI1KGh? M1jJS2ROW09? NE\POZlld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZicEWz MkXxNlE2PDh3OEK=
GM11272 M{fSWWZ2dmO2aX;uJGF{e2G7 NX3r[HlqOC5zIN88US=> M2fFfVczKGh? M2r3SWROW09? NFj5[Xhld2W|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO|aX;u NG\BOoIzOTh2MEexOi=>
MDA-MB-231 M2j2ZmtqdmG|ZTDBd5NigQ>? MW[xNEDPxE1? MXG1JI1qdg>? M4DrSmROW09? NVvUU2lu\G:nczDuc5QhcW6qaXLpeEBJTEGFMnG= Ml;WNlM1QTN2NEm=
MDA-MB-231 NGq2Uo5McW6jc3WgRZN{[Xl? MX[xJO69VQ>? MkfmNlQhcA>? M{XUSGROW09? NV\v[ndT\G:nczDuc5QhcW6qaXLpeEBJTEGFNjDhd5Nme3OnZDDhd{Bi[2W2eXzheIlwdiCuZY\lcJMhd2ZidIXieYxqdg>? NUXoUmtVOjN2OUO0OFk>
K562 MoXlT4lv[XOnIFHzd4F6 M{\IN4Rw\XNibn;0JIlvcGmkaYSgTGRCSw>? NVPwWldQOjN3OUGxNVE>
Jurkat MojoR5l1d3SxeHnjJGF{e2G7 NHHv[lMzOCEQvF2= NGXNNoY4OiCq M3jrPWROW09? MWTuc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36= M33welI1OzB2M{S4
HCT116 NIXYUJBCeG:ydH;zbZMhSXO|YYm= NX\aUIhYOyEQvF2= MnH1NlQhcA>? NULtT5pCTE2VTx?= NECzSmdld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bxem:2ZXnuJIxmfmWu NGPJTZMzPDd4NkW2NC=>
KASUMI-1 NXvl[odoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPDTYJKSzVyPUm5MlE4KG6P NXzmZ5VwW0GQR1XS
KARPAS-45 NEfZcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF5Mz64PUBvVQ>? NIP3RnJUSU6JRWK=
BHT-101 NV7BW21HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHWRYVKSzVyPUK0OE4yQCCwTR?= NWG5SHZRW0GQR1XS
H9 NInMbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PD[2lEPTB;MkW1MlA1KG6P MVjTRW5ITVJ?
PA-1 M1XOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DGXGlEPTB;Mki2MlI3KG6P MXLTRW5ITVJ?
NEC8 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrtTWM2OD1{OEmuN|ghdk1? M4nwVHNCVkeHUh?=
MHH-PREB-1 NWXKVI41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rrSGlEPTB;Mkm0MlU{KG6P NUTJfIg6W0GQR1XS
NB7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPQOG9KSzVyPUO0OU44PCCwTR?= MUTTRW5ITVJ?
A3-KAW NX:3TW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fHUmlEPTB;NECwMlU6KG6P MmDtV2FPT0WU
NB69 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Db3BMUUN3ME20NVEvPzFibl2= NHPLXnpUSU6JRWK=
EoL-1-cell M3XCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXIXINKSzVyPUS1OFI2KG6P MWPTRW5ITVJ?
CHP-212 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHX[2JKSzVyPUS1O{42OyCwTR?= MVvTRW5ITVJ?
C2BBe1 M2e2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR5Mj6xPUBvVQ>? NV2wSZZwW0GQR1XS
697 M1TMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HhXWlEPTB;NEezMlQyKG6P MXvTRW5ITVJ?
BCPAP NXvPZlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\FUGlEPTB;NUCxMlQzKG6P MWPTRW5ITVJ?
L-363 NI\lWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVyMz6xJI5O M{nYT3NCVkeHUh?=
ES8 NYPZOG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKyO3hKSzVyPUWyN{42OyCwTR?= M2fHc3NCVkeHUh?=
BE-13 M1PNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7xbIlLUUN3ME21NlYvQTZibl2= NIS4TGFUSU6JRWK=
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULFe4RqUUN3ME21N|cvQTJibl2= MXLTRW5ITVJ?
HD-MY-Z M1PZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M171d2lEPTB;NUO4MlE{KG6P Mo[yV2FPT0WU
NKM-1 NXzLV2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTV2ND6yO{BvVQ>? M1XQXXNCVkeHUh?=
NCI-H720 NXf4TJgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjucIRFUUN3ME21OlAvOThibl2= M3LOXnNCVkeHUh?=
KY821 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXwTWM2OD13NkOuNlUhdk1? M{[yN3NCVkeHUh?=
OVCAR-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvRWHZKSzVyPUW3Ok4yOSCwTR?= NWj6enN1W0GQR1XS
CTV-1 NX2yU|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrempKSzVyPUW4NU42PiCwTR?= M{fCbnNCVkeHUh?=
P12-ICHIKAWA NIXzVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PNdmlEPTB;NUm2MlUyKG6P NWixUZRYW0GQR1XS
DB NGDmPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjlXI8yUUN3ME21PVgvPTdibl2= MUXTRW5ITVJ?
CHL-1 M3TrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3tT5htUUN3ME22OFIvODhibl2= MUPTRW5ITVJ?
A4-Fuk NHm2dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWxUpNKSzVyPU[0OE46OSCwTR?= NFTkNWFUSU6JRWK=
MV-4-11 NFfQWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz1TWM2OD14NUmuNUBvVQ>? MlH0V2FPT0WU
RPMI-8226 M1vxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HFdmlEPTB;Nke4MlE5KG6P M1qySXNCVkeHUh?=
NB14 NUm0WnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHRdnZKUUN3ME22PVYvQTVibl2= NFjHRWdUSU6JRWK=
DOHH-2 NVu3eY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrVT3drUUN3ME23NFYvPjhibl2= M3[xVXNCVkeHUh?=
D-423MG NInGV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0[GlEPTB;N{C2Mlg6KG6P MlvYV2FPT0WU
D-283MED MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\tWYFKSzVyPUexOE4yPCCwTR?= MUTTRW5ITVJ?
ES1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLFOlRVUUN3ME23NlQvPCCwTR?= MU\TRW5ITVJ?
GOTO M17oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfKdY9KSzVyPUeyPU4yOiCwTR?= Ml\XV2FPT0WU
NCI-H209 NVHaVZAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDTplKSzVyPUeyPU46KG6P MmDSV2FPT0WU
MOLT-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\wWmlEPTB;N{O4Mlk5KG6P MVTTRW5ITVJ?
ATN-1 M{TOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm3SXhKSzVyPUe0NE4zQCCwTR?= M4XHOnNCVkeHUh?=
DU-4475 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOwOXJzUUN3ME23OVEvQTFibl2= Mli5V2FPT0WU
NB10 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5TWM2OD15NUGuPVIhdk1? MVHTRW5ITVJ?
KG-1 M2roO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrTV|JYUUN3ME23O|UvPDVibl2= NEXnO4NUSU6JRWK=
MOLT-4 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHGTWM2OD15OEeuOFYhdk1? MVLTRW5ITVJ?
TE-1 NXTVNGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn4flNRUUN3ME23PVEvOSCwTR?= MlTtV2FPT0WU
SBC-1 NHjGWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfwSJBKSzVyPUe5N{45PCCwTR?= M3PRVHNCVkeHUh?=
HEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rnOGlEPTB;OEC2MlA5KG6P MUHTRW5ITVJ?
SK-MEL-2 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof5TWM2OD16MEmuOFQhdk1? MkDxV2FPT0WU
KU812 NXfpXIVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXDTodKSzVyPUixN{4yKG6P MV3TRW5ITVJ?
RPMI-8866 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\xO2dLUUN3ME24NVMvPjdibl2= NITlU3pUSU6JRWK=
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDw[pBKSzVyPUixOE43PiCwTR?= MoKxV2FPT0WU
LU-139 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTh{Mj64OkBvVQ>? MVHTRW5ITVJ?
RS4-11 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTh|Mj60OUBvVQ>? NX62e49wW0GQR1XS
EW-18 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fiVmlEPTB;OEOyMlk3KG6P NFnSNHhUSU6JRWK=
P30-OHK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDvTWM2OD16M{WuO{BvVQ>? M323enNCVkeHUh?=
D-566MG NWD6UYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHN4xKSzVyPUizPE43OiCwTR?= MYLTRW5ITVJ?
HSC-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLDdI1KSzVyPUi0Ok42OSCwTR?= NE[2UZVUSU6JRWK=
QIMR-WIL NG\CdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTh4Mj6wN{BvVQ>? MYnTRW5ITVJ?
SW954 NF\2PVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqwTWM2OD16NkOuNVYhdk1? NXmy[Gl1W0GQR1XS
HGC-27 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLFTWM2OD16N{KuN|Qhdk1? MmT3V2FPT0WU
HH MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfjTWM2OD16OUSuNVIhdk1? MYXTRW5ITVJ?
KE-37 NWLWZpoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;QSHNsUUN3ME24PVQvPjJibl2= MlLXV2FPT0WU
SK-N-DZ MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnkTWM2OD17MECuOFMhdk1? NH\WVVNUSU6JRWK=
J-RT3-T3-5 NGTpZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnZToNKSzVyPUmxNE41QSCwTR?= M4rwT3NCVkeHUh?=
A427 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3DNWtSUUN3ME25NlAvQDRibl2= MnnGV2FPT0WU
ECC10 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n5R2lEPTB;OUS1Mlg4KG6P MlrXV2FPT0WU
EW-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r3XWlEPTB;OUS3MlI3KG6P MnvCV2FPT0WU
MIA-PaCa-2 NWLIV217T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37jNGlEPTB;OUS5MlEzKG6P M3fOUXNCVkeHUh?=
HCC2218 M1\idWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTw[phKSzVyPUm1PE41QCCwTR?= MoHwV2FPT0WU
HAL-01 NHPvVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTl4OD6wOEBvVQ>? NULzO|RRW0GQR1XS
RD MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHtUWh1UUN3ME25O|QvPDVibl2= M4HCe3NCVkeHUh?=
SK-N-AS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTl6OD6xJI5O MVnTRW5ITVJ?
ML-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3PTWM2OD1zLkCwOFA4KM7:TR?= M2\wT3NCVkeHUh?=
MEL-HO NFrqNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTG[WRqUUN3ME2xMlAxPTh{IN88US=> M{HCRXNCVkeHUh?=
MS-1 NX75c3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnpTWM2OD1zLkCwOlE4KM7:TR?= Mof6V2FPT0WU
NCI-SNU-1 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMEKzN|Eh|ryP MlP6V2FPT0WU
8505C M{DYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG0UFNpUUN3ME2xMlAzOzNzIN88US=> M2DncnNCVkeHUh?=
MN-60 NFzMWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13CeGlEPTB;MT6wNlY5KM7:TR?= NEK3fYdUSU6JRWK=
SAS NIPmfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwMESwPFEh|ryP M3jxd3NCVkeHUh?=
EFM-19 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTRmlEPTB;MT6wOFg4QSEQvF2= NXzoR29xW0GQR1XS
Ca9-22 NYLrOJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrJ[45KSzVyPUGuNFUyODdizszN MX7TRW5ITVJ?
NBsusSR NEnrZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj2fFVxUUN3ME2xMlA2OTZ4IN88US=> MWPTRW5ITVJ?
NB13 NUDlUZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH2SXlKSzVyPUGuNFU2ODFizszN M3jmR3NCVkeHUh?=
SF295 M3TsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjETWM2OD1zLkC2OlI1KM7:TR?= MkTnV2FPT0WU
U-2-OS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;EU5FDUUN3ME2xMlA4QTFzIN88US=> MlTvV2FPT0WU
NCI-H526 NGTDNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPETWM2OD1zLkC4NlkyKM7:TR?= M{HaU3NCVkeHUh?=
KMOE-2 M4r5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LDSGlEPTB;MT6wPVQzOiEQvF2= M3nPWHNCVkeHUh?=
RCM-1 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPWZ4FUUUN3ME2xMlEzOTB{IN88US=> MnPHV2FPT0WU
MC116 NYO4U4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1THV7UUN3ME2xMlE{PjJzIN88US=> NVnSW2ZyW0GQR1XS
NCI-H1092 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnHWoNKSzVyPUGuNVU1ODZizszN M3r2SHNCVkeHUh?=
EW-3 NY\WVpdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rBO2lEPTB;MT6xO|IyOiEQvF2= NXq4bJZ7W0GQR1XS
HCT-116 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli4TWM2OD1zLkG3O|Uh|ryP M2SzVnNCVkeHUh?=
MC-IXC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4iycGlEPTB;MT6xO|g5OSEQvF2= NFXQPGJUSU6JRWK=
LB1047-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMUizNVIh|ryP NXHUbHpwW0GQR1XS
VM-CUB-1 NW\IXVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Di[2lEPTB;MT6xPVExQCEQvF2= NYnEXW9jW0GQR1XS
NB5 M1W4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaboJWUUN3ME2xMlE6QDV4IN88US=> NEnsUYRUSU6JRWK=
SKG-IIIa NEPzcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNcIFKSzVyPUGuNlM1PjRizszN MlfyV2FPT0WU
HO-1-N-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PGOGlEPTB;MT6yN|g{PSEQvF2= MXvTRW5ITVJ?
EFO-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHscJZsUUN3ME2xMlI2ODR|IN88US=> Ml\rV2FPT0WU
MHH-NB-11 NWXyXJVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPMU2xKSzVyPUGuNlg{OjlizszN NWrmfWY3W0GQR1XS
SW620 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD1zLkK5NFE5KM7:TR?= MY\TRW5ITVJ?
MOLT-16 NUj1OpN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwMkm3PVch|ryP M3\acXNCVkeHUh?=
NTERA-S-cl-D1 NIrBco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTNU21PUUN3ME2xMlMyPzZzIN88US=> MUfTRW5ITVJ?
VA-ES-BJ NVL5PYhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK3TWM2OD1zLkOyOFc4KM7:TR?= Moj2V2FPT0WU
HCC1419 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni4TWM2OD1zLkO0NFI4KM7:TR?= NVvzS5gxW0GQR1XS
NCI-H69 M1PUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT0PJJKSzVyPUGuN|QyOTJizszN NYTMZVhWW0GQR1XS
DEL M4XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rBR2lEPTB;MT6zOVE3OiEQvF2= M1jVbXNCVkeHUh?=
LXF-289 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG2TWM2OD1zLkO1NlQh|ryP MYDTRW5ITVJ?
EW-11 M3vUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf0Zm5JUUN3ME2xMlM3ODJ4IN88US=> NFTONWdUSU6JRWK=
KP-4 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwM{ewPFUh|ryP M1\hVHNCVkeHUh?=
NOS-1 M{HUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rnOGlEPTB;MT60NVE6PCEQvF2= M{nLNHNCVkeHUh?=
SK-NEP-1 M4XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\aTVg1UUN3ME2xMlQyPjl|IN88US=> MVPTRW5ITVJ?
LAMA-84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNEO5OFUh|ryP NIq4d5VUSU6JRWK=
ES5 M4fiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\KTWM2OD1zLkS0N{DPxE1? M1TVcHNCVkeHUh?=
HuO9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwNEWzOlIh|ryP NETSV3VUSU6JRWK=
COLO-684 NGLnPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nYUWlEPTB;MT60OlEyQCEQvF2= M1TyO3NCVkeHUh?=
EW-24 M3PCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwNE[1N|Eh|ryP MVfTRW5ITVJ?
BV-173 NYXYR3k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:3d4JRUUN3ME2xMlQ4OjlzIN88US=> M{XKW3NCVkeHUh?=
NCI-H1770 NGrzR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13MR2lEPTB;MT60PFU{PiEQvF2= M4DWN3NCVkeHUh?=
HuP-T4 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2wcFBKSzVyPUGuOFk{KM7:TR?= Mo\KV2FPT0WU
TYK-nu M4mxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn65TWM2OD1zLkS5PFUyKM7:TR?= M1iy[XNCVkeHUh?=
YH-13 NIC4ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\HTWM2OD1zLkS5PFk1KM7:TR?= M3LoS3NCVkeHUh?=
H4 NHn5dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jU[GlEPTB;MT61NFkyOiEQvF2= MV3TRW5ITVJ?
OVCAR-8 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwNUS0O|ch|ryP NFXUOIxUSU6JRWK=
NCI-H23 NHTGbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwNUS2OFUh|ryP M3:4WXNCVkeHUh?=
ES7 NHy5SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ziW2lEPTB;MT61OFc4OyEQvF2= MorUV2FPT0WU
COR-L88 M4P1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PwW2lEPTB;MT61OlQzPCEQvF2= MUnTRW5ITVJ?
TI-73 NWfoWoVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17MNGlEPTB;MT61PVA3KM7:TR?= NILaWFJUSU6JRWK=
RT-112 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLK[W9QUUN3ME2xMlU6Ojh2IN88US=> NX[0dpZ1W0GQR1XS
HuO-3N1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH2TWM2OD1zLkW5N|g2KM7:TR?= MoKyV2FPT0WU
HC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW5eYhJUUN3ME2xMlU6QDZ4IN88US=> NF60doVUSU6JRWK=
HT55 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TtVGlEPTB;MT62OVE{OSEQvF2= M3r5bHNCVkeHUh?=
IA-LM NGfUUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3Vb2VKSzVyPUGuOlkzPzhizszN NXnT[4xrW0GQR1XS
EM-2 M3XnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe5fWZ{UUN3ME2xMlcxODF2IN88US=> MkmzV2FPT0WU
MHH-ES-1 NFrhfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwN{C0N|Uh|ryP NUnkNHp[W0GQR1XS
CAL-27 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLaTWM2OD1zLkewOlIyKM7:TR?= MlfjV2FPT0WU
COLO-800 M1PlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXye41LUUN3ME2xMlcyOTd7IN88US=> MUHTRW5ITVJ?
HCE-T NHv2PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XJ[WlEPTB;MT63NVUh|ryP NGj0XG1USU6JRWK=
CAMA-1 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHpTWM2OD1zLkexPVcyKM7:TR?= M2DDdHNCVkeHUh?=
LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz3TWM2OD1zLkeyNVEh|ryP NGTsVmVUSU6JRWK=
NH-12 NFrGUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmxTWM2OD1zLkeyOlkyKM7:TR?= M1znUnNCVkeHUh?=
TCCSUP MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZOWlEPTB;MT63NlgzQSEQvF2= NIfofnZUSU6JRWK=
MDA-MB-361 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjnNnVYUUN3ME2xMlc{OTV5IN88US=> NWXjb3A3W0GQR1XS
EW-16 M3;hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juN2lEPTB;MT63OFExPyEQvF2= MWHTRW5ITVJ?
SNU-423 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwN{W4Nlch|ryP NHPFZnBUSU6JRWK=
Daoy NIfmNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPGTWM2OD1zLke2N|E6KM7:TR?= MXfTRW5ITVJ?
ES4 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjco1VUUN3ME2xMlc5PzRzIN88US=> MnzGV2FPT0WU
PFSK-1 M3HtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwOECzO{DPxE1? MmDMV2FPT0WU
ES3 NGi3T49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsbWRuUUN3ME2xMlgzPjhzIN88US=> NXHxSGpEW0GQR1XS
ONS-76 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DHXmlEPTB;MT64Nlg6PyEQvF2= NXfOTIZZW0GQR1XS
JVM-3 M3HOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nFfmlEPTB;MT64OVQ2OSEQvF2= NWfSeJRMW0GQR1XS
OS-RC-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PXfGlEPTB;MT64O|E2OSEQvF2= NIq4NnNUSU6JRWK=
COLO-320-HSR MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwOEixPVch|ryP NEHZSJJUSU6JRWK=
HN MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwOEi3NlUh|ryP MXnTRW5ITVJ?
HT M3Hxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrLNWpYUUN3ME2xMlg5QTR5IN88US=> MoPEV2FPT0WU
LoVo MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfub3dKUUN3ME2xMlg6QDFizszN NXPOcnZxW0GQR1XS
CGTH-W-1 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[1e4RKSzVyPUGuPFk6PDZizszN MlzvV2FPT0WU
NB6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwOUGyPVgh|ryP NXXiblZyW0GQR1XS
EW-22 M2HxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv2eYdVUUN3ME2xMlkzQDh5IN88US=> NVmxVWxGW0GQR1XS
ES6 NYXNSIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfWSlZKSzVyPUGuPVM3OzFizszN NFTzbW9USU6JRWK=
SCC-15 M3TsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7GTWM2OD1zLkmzPFE6KM7:TR?= NGixV4NUSU6JRWK=
HL-60 NEP2cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O3cWlEPTB;MT65N|kxOiEQvF2= NH\SV49USU6JRWK=
human HOP-92 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[yOmlEPTB;MT65OFA3PSEQvF2= MUXTRW5ITVJ?
SW626 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrkTWM2OD1zLkm0PFk6KM7:TR?= MVnTRW5ITVJ?
HEC-1 M3XRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OwTGlEPTB;MT65OVM3KM7:TR?= MXPTRW5ITVJ?
LB2241-RCC NETke2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T5cWlEPTB;MT65PFI{OSEQvF2= NF6yOWpUSU6JRWK=
Ramos-2G6-4C10 NUXK[lZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\CTWM2OD1zLkm5OFk{KM7:TR?= NGq3co9USU6JRWK=
A101D Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwMkCzNFMh|ryP NInSeopUSU6JRWK=
NCI-H446 NUns[2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD3[G8xUUN3ME2yMlA1PTl7IN88US=> NHrOWlZUSU6JRWK=
SBC-5 NX3tWlJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfRNopEUUN3ME2yMlA3OTR5IN88US=> MkLIV2FPT0WU
HOS MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP5dYx{UUN3ME2yMlA4PjV|IN88US=> M4jsN3NCVkeHUh?=
K5 M4jkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsPWlEPTB;Mj6wO|gyOSEQvF2= M{KyVHNCVkeHUh?=
HLE M{nzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DaUmlEPTB;Mj6wPFUzQSEQvF2= M2nkWHNCVkeHUh?=
HSC-2 NXTGb|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfNNpBFUUN3ME2yMlEzQDl6IN88US=> M4LtT3NCVkeHUh?=
LCLC-97TM1 M3HYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwMUS1PFMh|ryP M2XjU3NCVkeHUh?=
DMS-273 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF71dnlKSzVyPUKuNVQ5OzdizszN NFnNcIpUSU6JRWK=
TE-8 MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwMUW3OlUh|ryP M1nCTHNCVkeHUh?=
DSH1 NVXPV|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrPS4tSUUN3ME2yMlE3Ozl6IN88US=> MnPuV2FPT0WU
CAL-51 M{nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwMU[2PVkh|ryP M{\EfXNCVkeHUh?=
IST-SL1 M2\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwMU[4OFQh|ryP MXLTRW5ITVJ?
GCT NGLRV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm3V41KSzVyPUKuNVc4PyEQvF2= NUDYcYRPW0GQR1XS
SW948 M2r3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPlRnRKSzVyPUKuNVg1PTZizszN Mme1V2FPT0WU
NOMO-1 NHf1NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwMUmzNVch|ryP MUTTRW5ITVJ?
C8166 M4X5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7kfYNKSzVyPUKuNlE{OzRizszN MWnTRW5ITVJ?
OC-314 NWK1N21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPCdJRKSzVyPUKuNlMzPTlizszN M2TId3NCVkeHUh?=
CAL-39 M1TKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwMkO2NlYh|ryP NVPUR2J5W0GQR1XS
MDA-MB-453 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn0b49KSzVyPUKuNlQzPzVizszN NV3GVXdsW0GQR1XS
A673 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2TWM2OD1{LkK1PFYzKM7:TR?= Mo\sV2FPT0WU
HTC-C3 M4LzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rmUGlEPTB;Mj6yOlg2KM7:TR?= Mmm1V2FPT0WU
NCI-H1666 NUDhUZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnlTWM2OD1{LkK4NVEyKM7:TR?= NFrPNYdUSU6JRWK=
PSN1 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjkTWM2OD1{LkK4PVE{KM7:TR?= MYXTRW5ITVJ?
GI-1 NVrvNYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:yOmlEPTB;Mj6zNFU1OyEQvF2= MnTXV2FPT0WU
HuH-7 M3[3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXaPI5KSzVyPUKuN|A3OzdizszN MULTRW5ITVJ?
JAR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTGTWM2OD1{LkOxPVg4KM7:TR?= M1z1U3NCVkeHUh?=
5637 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTtV3hEUUN3ME2yMlMzOTJ7IN88US=> NXf1OIF5W0GQR1XS
GB-1 NX7FfodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULab5ZNUUN3ME2yMlMzOzN3IN88US=> NFHXZndUSU6JRWK=
KP-N-YS NWrrVG04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH76dGZKSzVyPUKuN|I3OTVizszN NV;3fGdMW0GQR1XS
OAW-42 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OzeWlEPTB;Mj6zN|QyPiEQvF2= NHj6fpBUSU6JRWK=
8-MG-BA Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[wdWRKSzVyPUKuN|M6ODZizszN M{nxdXNCVkeHUh?=
RH-18 NFG5bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDCWlZKSzVyPUKuN|UxOjJizszN MlPTV2FPT0WU
NCI-H1155 M1S2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPqTWM2OD1{LkO2O|I2KM7:TR?= NXTxfpc2W0GQR1XS
NB17 M3ftTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrSN|E3UUN3ME2yMlM5OjR|IN88US=> MXzTRW5ITVJ?
NCI-H1437 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwNEG4O|Mh|ryP NUC2SGFFW0GQR1XS
SN12C Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwNEOyNVQh|ryP MYPTRW5ITVJ?
HSC-3 M4XYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwNES1NFkh|ryP M3;1PXNCVkeHUh?=
GAMG NETjfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPZ2lKSzVyPUKuOFQ2PjFizszN NITKcYpUSU6JRWK=
HT-1080 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXCTWtKSzVyPUKuOFQ5PjRizszN NYnuT|ZCW0GQR1XS
A549 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0PVlvUUN3ME2yMlQ1QDl|IN88US=> MXLTRW5ITVJ?
KNS-62 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe1VYp6UUN3ME2yMlQ2ODZzIN88US=> NFTUV|VUSU6JRWK=
YKG-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e5NGlEPTB;Mj60OVQ{PyEQvF2= NIDRfolUSU6JRWK=
LU-134-A Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDqTWM2OD1{LkS3NFA5KM7:TR?= NUTTW5hEW0GQR1XS
FADU NE\Re5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjfWpVUUN3ME2yMlQ4OTZ{IN88US=> NVjQ[pBlW0GQR1XS
TGBC11TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3HPYlKSzVyPUKuOFcyPzdizszN Mnm0V2FPT0WU
HT-3 NELJZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaTWM2OD1{LkS5OVM2KM7:TR?= MWXTRW5ITVJ?
NCI-H2170 NX74bGhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TlOWlEPTB;Mj61NFU1QSEQvF2= MVzTRW5ITVJ?
Mo-T M2DQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXqTWM2OD1{LkWwPVI4KM7:TR?= MnjRV2FPT0WU
CCRF-CEM NUnYdXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\iTWM2OD1{LkWzNFQ{KM7:TR?= NXHI[JpyW0GQR1XS
KU-19-19 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\wTWM2OD1{LkWzOVE{KM7:TR?= MnrJV2FPT0WU
NCI-H1048 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPNTWM2OD1{LkW1NFI2KM7:TR?= NGD0UGpUSU6JRWK=
KOSC-2 NVLaSG9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NdHRKSzVyPUKuOVYxPzZizszN MXPTRW5ITVJ?
A431 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjNUGJqUUN3ME2yMlU3OzN3IN88US=> M17vTnNCVkeHUh?=
COR-L23 M4n1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HM[GlEPTB;Mj61PFU3PiEQvF2= NX3zSWRCW0GQR1XS
MKN28 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KyTmlEPTB;Mj61PVA{PyEQvF2= NILTdItUSU6JRWK=
22RV1 M2rRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwNUmyO|Qh|ryP NVL5To41W0GQR1XS
ABC-1 NXLEcIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLETWM2OD1{Lk[wOFYh|ryP M3K1VnNCVkeHUh?=
NCI-H2126 NHXsOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwNkC5PFQh|ryP M1\iZXNCVkeHUh?=
DoTc2-4510 NYTldoRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn5[XhZUUN3ME2yMlYzOTh3IN88US=> MkfpV2FPT0WU
SCC-4 M2\xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor3TWM2OD1{Lk[zNFEzKM7:TR?= NXjFOVRWW0GQR1XS
NCI-H661 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNkSwPFUh|ryP NIDvU3ZUSU6JRWK=
RPMI-2650 M2e5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjLdJNlUUN3ME2yMlY1OTR|IN88US=> MlHjV2FPT0WU
NCI-H510A MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jvRmlEPTB;Mj62OFQzPiEQvF2= M2fud3NCVkeHUh?=
BPH-1 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjpdGFLUUN3ME2yMlY2QDVizszN M4jr[3NCVkeHUh?=
M14 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD1{Lk[2PVk{KM7:TR?= MnrxV2FPT0WU
G-402 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyU2lEPTB;Mj63NFQ2OSEQvF2= MX;TRW5ITVJ?
AsPC-1 NFuwc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImweXJKSzVyPUKuO|EyPyEQvF2= Mn6zV2FPT0WU
NB12 NYjzfmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD1{LkexO|Eh|ryP NFrRWFRUSU6JRWK=
SK-HEP-1 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXXTWM2OD1{Lke0N|kyKM7:TR?= NYC3XlhiW0GQR1XS
U-266 NIjUb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRZ2lEPTB;Mj63O|EzOSEQvF2= NX7J[ms6W0GQR1XS
AM-38 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;mVGlEPTB;Mj63O|M2PSEQvF2= NEPP[XlUSU6JRWK=
PC-14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\HdGlEPTB;Mj64NFUyKM7:TR?= NHrXR|FUSU6JRWK=
EGI-1 NFPhbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCbmxKSzVyPUKuPFE4PDNizszN NWj1bG9oW0GQR1XS
LS-411N NULjemFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zlbWlEPTB;Mj64NlM{KM7:TR?= NF74WIZUSU6JRWK=
BFTC-905 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYZVBKSzVyPUKuPFU2OjNizszN NFrNc5NUSU6JRWK=
CaR-1 NVO2epI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS0Z2pGUUN3ME2yMlg3KM7:TR?= NVnLU4ZYW0GQR1XS
NCI-H292 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwOE[1PVYh|ryP NX;WOFU3W0GQR1XS
8305C NVzmXoVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwOE[2OFUh|ryP MoPyV2FPT0WU
SNU-449 NXzMfY5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnJTFJKSzVyPUKuPFkyQDJizszN NILIPZBUSU6JRWK=
LCLC-103H M{ToSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlTWM2OD1{LkmwOFM5KM7:TR?= NETpNlVUSU6JRWK=
SW1573 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1{Lkm2NFgzKM7:TR?= MXjTRW5ITVJ?
MLMA MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPBO|hKSzVyPUKuPVY4OTdizszN NXLsPZF{W0GQR1XS
NCI-H1355 M3TFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDyTWM2OD1|LkCwO|k3KM7:TR?= NXvKT4RwW0GQR1XS
RMG-I M2e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rlTmlEPTB;Mz6wNlU6OiEQvF2= M{jlWXNCVkeHUh?=
BB65-RCC MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP6TWM2OD1|LkCzN|E1KM7:TR?= Mlj5V2FPT0WU
PC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHyVIZKSzVyPUOuNFM5PzRizszN MYLTRW5ITVJ?
SF268 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP3TWM2OD1|LkC0OVI{KM7:TR?= MXHTRW5ITVJ?
NCI-H810 NV\oVGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwMES4NlMh|ryP NYGyN492W0GQR1XS
MEG-01 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTXVXpKSzVyPUOuNFYyPjRizszN MVrTRW5ITVJ?
SW13 MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNwMEe4OFch|ryP NEexR2pUSU6JRWK=
RH-1 M33HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMUCyO|gh|ryP M2njXXNCVkeHUh?=
GT3TKB M1nWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwMUGyPFMh|ryP NFnaVJRUSU6JRWK=
TK10 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP3TWM2OD1|LkGzO|I1KM7:TR?= NWDuVndpW0GQR1XS
T-24 NVnsVlRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNwMUWwO{DPxE1? M{H4XnNCVkeHUh?=
A498 NWTrZ5duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnHWmd{UUN3ME2zMlIxQDdzIN88US=> NI\4e2pUSU6JRWK=
GR-ST MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO4TWM2OD1|LkKyNVM6KM7:TR?= NH;yfVVUSU6JRWK=
LB2518-MEL Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nOeGlEPTB;Mz6yNlM6QCEQvF2= MW\TRW5ITVJ?
T47D M1XQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwMkO2Nlch|ryP NF3GVGNUSU6JRWK=
NCI-H1651 NWS0VFZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL2dJFSUUN3ME2zMlI1PjR2IN88US=> MWPTRW5ITVJ?
EC-GI-10 NVPlfncyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwMk[xOVMh|ryP NWXjc3ZVW0GQR1XS
HT-29 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDNVWRKSzVyPUOuNlY3OTRizszN M3PrW3NCVkeHUh?=
GI-ME-N Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvZTWM2OD1|LkK5OVEyKM7:TR?= NIDo[ZdUSU6JRWK=
SW756 NVzSPGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJ[mxFUUN3ME2zMlI6PjJ7IN88US=> M3zINnNCVkeHUh?=
RKO NEm0O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPcmlEPTB;Mz6zNFc2PyEQvF2= MUfTRW5ITVJ?
NCI-H1563 NIPlSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfETWM2OD1|LkOzNFE5KM7:TR?= NFu5fZNUSU6JRWK=
DJM-1 M2HRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwM{e2O|Qh|ryP Mn3UV2FPT0WU
L-428 M3vrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD1|LkSwNFQ2KM7:TR?= M2f5fXNCVkeHUh?=
NCI-H2122 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluzTWM2OD1|LkSxN|EzKM7:TR?= MWPTRW5ITVJ?
Ca-Ski MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTNR4kzUUN3ME2zMlQ2PDNizszN MoXaV2FPT0WU
639-V M1PYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXNPJpKSzVyPUOuOFYxPTdizszN MljiV2FPT0WU
SW1116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2yTWM2OD1|LkS2NlY6KM7:TR?= NV\1c|ZnW0GQR1XS
DMS-114 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknHTWM2OD1|LkS3NFY3KM7:TR?= M2C2U3NCVkeHUh?=
MZ2-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHrdG9KSzVyPUOuOFc3QDFizszN MYLTRW5ITVJ?
COLO-829 NW\Ce25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnQSlRKSzVyPUOuOVAxPzNizszN M1XnV3NCVkeHUh?=
J82 M2LRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL2SndKSzVyPUOuOVA2PyEQvF2= NUT2WpNEW0GQR1XS
EW-13 NXjDcYluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv3NXI5UUN3ME2zMlUzPTFizszN Ml:4V2FPT0WU
RXF393 NEjTV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\DUmxKSzVyPUOuOVMzQTRizszN NEHYVnNUSU6JRWK=
CAL-62 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXtTG9KSzVyPUOuOVQ2OTRizszN MVLTRW5ITVJ?
OCUB-M NILIPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm2O415UUN3ME2zMlU1PjZ3IN88US=> NEfUZ3VUSU6JRWK=
BT-474 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNkOzNUDPxE1? M{G2TXNCVkeHUh?=
KYSE-180 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr3R41KSzVyPUOuOlM{PzJizszN MWnTRW5ITVJ?
NCI-H650 M4rseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITSeWJKSzVyPUOuOlQzQDdizszN MWTTRW5ITVJ?
Detroit562 M{DnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwNkWwNlIh|ryP M1WyZnNCVkeHUh?=
SW48 NGLiPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX2OYc4UUN3ME2zMlY2PjV5IN88US=> NFvsWGhUSU6JRWK=
KYSE-450 NV\4fHdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNwNki1PFIh|ryP M4HN[XNCVkeHUh?=
KYSE-510 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvSTWM2OD1|LkeyNVgyKM7:TR?= MUjTRW5ITVJ?
GP5d NYPNPYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPBcXpqUUN3ME2zMlczQTVizszN MV;TRW5ITVJ?
RPMI-7951 M4rDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwN{S3NlMh|ryP NVrxV5lPW0GQR1XS
Becker MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3bnByUUN3ME2zMlc2ODF{IN88US=> MlTFV2FPT0WU
WM-115 NWnnRplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmz[JZKSzVyPUOuO|gyQTVizszN MYLTRW5ITVJ?
G-401 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwN{mwPFUh|ryP NVzBOmxpW0GQR1XS
PANC-08-13 NFvVXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kfJdKSzVyPUOuO|k3ODJizszN Mm\DV2FPT0WU
SW982 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6NWlEPTB;Mz64NFU2OSEQvF2= MV\TRW5ITVJ?
D-263MG M2\yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nscmlEPTB;Mz64NlA2OSEQvF2= NHvufI5USU6JRWK=
KM-H2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\rTWM2OD1|LkiyOlI1KM7:TR?= M3vEVnNCVkeHUh?=
SK-MEL-3 NXjsSZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwOEK4OFEh|ryP NF3aU3JUSU6JRWK=
NCI-H1581 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLCTWM2OD1|Lki0OFg5KM7:TR?= NHnLVoRUSU6JRWK=
LS-123 NVH2bIgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG5[4JKSzVyPUOuPFc6ODlizszN M36wRnNCVkeHUh?=
CAKI-1 M4LT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonaTWM2OD1|Lki5NFUzKM7:TR?= NGXESFdUSU6JRWK=
MEL-JUSO NXrzdVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1|Lki5NVU{KM7:TR?= MXzTRW5ITVJ?
HCE-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Tnb2lEPTB;Mz65NVY3OyEQvF2= MXfTRW5ITVJ?
TE-10 M{K5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17we2lEPTB;Mz65NlAyKM7:TR?= NWDTZXQ{W0GQR1XS
OVCAR-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIcoRKSzVyPUOuPVI5QDlizszN MV;TRW5ITVJ?
ETK-1 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW2U4NUUUN3ME2zMlk1PjN3IN88US=> NULQV5dSW0GQR1XS
A2780 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwMEW5OlYh|ryP M333WnNCVkeHUh?=
LU-65 NVrQfoNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHYT2RKSzVyPUSuNFc3OzNizszN MnzaV2FPT0WU
BHY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXkTWM2OD12LkGyOFk2KM7:TR?= NIHjSGRUSU6JRWK=
COR-L105 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPtN2JKSzVyPUSuNVMxPTFizszN NV\5dldLW0GQR1XS
CAL-12T NEDY[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjRRmtKSzVyPUSuNVMyODNizszN NYTjPFVwW0GQR1XS
SCH NYrQVmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPzdHZKSzVyPUSuNVU4PDNizszN MV3TRW5ITVJ?
CW-2 NULGTIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwMUmwNFEh|ryP MUnTRW5ITVJ?
HCC1806 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTRwMkCzNVIh|ryP NXi4WHRrW0GQR1XS
KP-N-YN NE\ocGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwMkC5Nlch|ryP NYj0doh[W0GQR1XS
T98G NXroT3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfSTWM2OD12LkKyNVU4KM7:TR?= NHzodoRUSU6JRWK=
CAL-54 M{\aRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD12LkKyN|gyKM7:TR?= MmXFV2FPT0WU
CAL-33 NGX3fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e2SGlEPTB;ND6yN|A3PCEQvF2= NXzNTGs{W0GQR1XS
SNU-C2B NF7hSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Hc3dPUUN3ME20MlI1PzZ7IN88US=> MWnTRW5ITVJ?
NUGC-3 NF72OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXzTWM2OD12LkK1OVA2KM7:TR?= NEf1ToNUSU6JRWK=
DOK MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS0TWM2OD12LkK2OVk{KM7:TR?= MoX0V2FPT0WU
MMAC-SF MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjwdmRKSzVyPUSuNlY5PTlizszN Mn[xV2FPT0WU
KYSE-70 NUT0OVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGTWM2OD12LkK5N|Qh|ryP NYLEZlRIW0GQR1XS
A204 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD6TWM2OD12LkO1PFA{KM7:TR?= M{HZdHNCVkeHUh?=
SCC-25 M3fiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwM{W4NVkh|ryP NGPTWohUSU6JRWK=
EPLC-272H MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjvfGNKSzVyPUSuN|g6PSEQvF2= Ml\PV2FPT0WU
CAL-120 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwM{i5PVIh|ryP MXXTRW5ITVJ?
LS-513 M371emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwNEKxPVgh|ryP MlLuV2FPT0WU
CAPAN-1 NFO4TpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faXmlEPTB;ND60NlM5OiEQvF2= MWrTRW5ITVJ?
ESS-1 M3G0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvTV3F3UUN3ME20MlQzPzJ2IN88US=> M1KzVXNCVkeHUh?=
GMS-10 NGjXRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRwNEK4NVkh|ryP NEDpVVZUSU6JRWK=
NCI-N87 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjmTWM2OD12LkWwPFY5KM7:TR?= NELV[4xUSU6JRWK=
HMV-II M3Th[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OwSGlEPTB;ND61NVc{KM7:TR?= NWX0fpVZW0GQR1XS
COLO-741 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CboVEUUN3ME20MlU2QTl2IN88US=> NEDIdldUSU6JRWK=
MKN45 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwNUe3N|Ih|ryP M3rhcHNCVkeHUh?=
OAW-28 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwNUizPVgh|ryP M2PwbnNCVkeHUh?=
OCI-AML2 M4LU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDXbY1KSzVyPUSuOlUzOzhizszN NEXLSnFUSU6JRWK=
MDA-MB-231 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD12LkewNlQ{KM7:TR?= NYTOW5VWW0GQR1XS
NCI-H1648 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\0TWM2OD12LkeyNlc{KM7:TR?= MkjCV2FPT0WU
NCI-H1792 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknVTWM2OD12Lke2NVA4KM7:TR?= MnTwV2FPT0WU
GCIY M{S5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPWW2NKSzVyPUSuO|c1OjRizszN NYDjWoF4W0GQR1XS
Hs-578-T NUWzRnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S0Z2lEPTB;ND63O|Y2PSEQvF2= MnHJV2FPT0WU
SW962 M3\0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fpOWlEPTB;ND63PFAyOSEQvF2= MlnqV2FPT0WU
NCI-H630 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DKOmlEPTB;ND63PFA5OSEQvF2= NV7ibYJHW0GQR1XS
786-0 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTRwN{i3O|Mh|ryP NWrnS4JjW0GQR1XS
FTC-133 M4nmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwN{myOlMh|ryP MmHxV2FPT0WU
BT-20 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PNZmlEPTB;ND63PVQzQSEQvF2= MkjyV2FPT0WU
Mewo NXraN2hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rncWlEPTB;ND64NVc1PyEQvF2= MYjTRW5ITVJ?
SW780 NFTJTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwOEW3OlYh|ryP MX\TRW5ITVJ?
OE33 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjBZ3RuUUN3ME20Mlg4PzF|IN88US=> NYD0N4pqW0GQR1XS
HCC1569 NEPxdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr0eVVKSzVyPUSuPFg1PThizszN MYPTRW5ITVJ?
TE-6 NXLqeHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zHcmlEPTB;ND65N|k4PyEQvF2= NXnxUlB4W0GQR1XS
SK-N-FI MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PYc2lEPTB;ND65OFQzOSEQvF2= NVTrfY1VW0GQR1XS
PANC-03-27 NYHoW2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwOUm5OlIh|ryP NEXSbnlUSU6JRWK=
MCF7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTVwMEC3N|gh|ryP MoHKV2FPT0WU
UACC-257 M{P0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonuTWM2OD13LkCyPFQ2KM7:TR?= M1T0eHNCVkeHUh?=
SW1088 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDWTWM2OD13LkCyPVQ1KM7:TR?= NUPzN3pDW0GQR1XS
A704 NFvXd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK3VplKSzVyPUWuNFMxPiEQvF2= M1HsZXNCVkeHUh?=
A2058 NYfVS2tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfyUndKSzVyPUWuNFU6ODhizszN M2LteXNCVkeHUh?=
Calu-3 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvuN3pUUUN3ME21MlA3PDV{IN88US=> MnzKV2FPT0WU
RERF-LC-MS NYfyWngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTVwME[5NFMh|ryP MYLTRW5ITVJ?
AU565 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHI[Yk4UUN3ME21MlA6PzB{IN88US=> MVXTRW5ITVJ?
DMS-79 M2\qfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTVwMUO4PFMh|ryP MUHTRW5ITVJ?
DK-MG M1nHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHKT495UUN3ME21MlE5PDN6IN88US=> M2PMXXNCVkeHUh?=
HuCCT1 NH6yOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKVGlEPTB;NT6yN|g2PiEQvF2= MUPTRW5ITVJ?
HT-144 NVX1dGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rLWGlEPTB;NT6yOFk5PyEQvF2= Mm[4V2FPT0WU
M059J MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTVwMkW3OkDPxE1? M3zqRXNCVkeHUh?=
COLO-792 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi3NIdxUUN3ME21MlI3OzV4IN88US=> MnHLV2FPT0WU
SF539 M{DPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\GWmlEPTB;NT6yOlY{OiEQvF2= NH:zZnhUSU6JRWK=
SK-UT-1 M323fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwMke3OVEh|ryP NXXFdodbW0GQR1XS
NCI-H1703 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HoNmlEPTB;NT6zOVgzPiEQvF2= M4[4VHNCVkeHUh?=
SW837 M3v5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwOGdLUUN3ME21MlM4QDd6IN88US=> M4TWUXNCVkeHUh?=
U251 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSwT41KSzVyPUWuN|kxQTZizszN NUfGfZQ2W0GQR1XS
SW1710 NUfKdFllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ScmlEPTB;NT60NVU2PCEQvF2= MkPZV2FPT0WU
NCI-H1299 NXP6doVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\UTWM2OD13LkS2N|M2KM7:TR?= NVLaSHBWW0GQR1XS
RVH-421 M2\Zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL5SoFKSzVyPUWuOFk6ODhizszN MUPTRW5ITVJ?
UM-UC-3 M4jVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTVwNkK2OVEh|ryP M1zZZXNCVkeHUh?=
MDA-MB-175-VII NWPqNpZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwNkSwOFEh|ryP MVrTRW5ITVJ?
KYSE-270 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2blZKSzVyPUWuOlYxOzFizszN M3PqeXNCVkeHUh?=
COLO-668 NGfoUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP3[XpKSzVyPUWuO|E{OiEQvF2= MknlV2FPT0WU
LN-405 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf0UINZUUN3ME21Mlc{ODh3IN88US=> M13TRnNCVkeHUh?=
HT-1376 M1z1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnafZNOUUN3ME21Mlc5ODV{IN88US=> NWLIbm5jW0GQR1XS
769-P NHvpTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwOE[3NVgh|ryP NGHGU4FUSU6JRWK=
HuP-T3 M3XFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfmTWM2OD13Lki4Olc4KM7:TR?= M4mw[nNCVkeHUh?=
MDA-MB-415 M3S2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HV[GlEPTB;NT65NlE{QSEQvF2= MYTTRW5ITVJ?
MKN7 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID3eIRKSzVyPUWuPVg5KM7:TR?= NUnHfmdVW0GQR1XS
KS-1 NFPuSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPKTWM2OD13Lkm4PFM3KM7:TR?= MnHMV2FPT0WU
647-V NHTJcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmyZ5lKSzVyPUWuPVkyPDhizszN M4O5cnNCVkeHUh?=
COLO-679 M{LiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZwMECyOVUh|ryP M1PXNXNCVkeHUh?=
AN3-CA M2PHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGRXVKSzVyPU[uNFM1PDFizszN M1;pcnNCVkeHUh?=
C32 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZPWlEPTB;Nj6xN|A{PCEQvF2= NHT1cHlUSU6JRWK=
KM12 NYrZSoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3TWM2OD14LkK0NFk6KM7:TR?= MVPTRW5ITVJ?
KINGS-1 M{Ppb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1OVJjUUN3ME22MlI3OTV{IN88US=> MnXSV2FPT0WU
KYSE-410 NHrLRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwM{C2OFUh|ryP NXPOUG5[W0GQR1XS
HPAF-II NWfGNohzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwM{W0PEDPxE1? MULTRW5ITVJ?
LAN-6 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D6PGlEPTB;Nj60PVY{OSEQvF2= NEDseZNUSU6JRWK=
LU-99A M2q1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPPTWM2OD14LkW1PVg6KM7:TR?= NEjGdWVUSU6JRWK=
SJSA-1 NVrBUm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTZwNU[zOFch|ryP NY[4cFFFW0GQR1XS
MSTO-211H NHixTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTZwN{KyN|Mh|ryP MXPTRW5ITVJ?
SW900 NWO4T4hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxZ5FKSzVyPU[uO|YzOjFizszN NEnWWIlUSU6JRWK=
LNCaP-Clone-FGC M{jxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TFRmlEPTB;Nj64NFQxOyEQvF2= Mn2yV2FPT0WU
OMC-1 NXHXS|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:wTWM2OD14Lki1OFAzKM7:TR?= MXjTRW5ITVJ?
IST-MEL1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHhUXk6UUN3ME22Mlg6PjZ7IN88US=> MXHTRW5ITVJ?
TE-9 M3HYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jqSWlEPTB;Nj64PVg1PyEQvF2= NFLtWpZUSU6JRWK=
NCI-H2030 M1HBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwOUGyNlYh|ryP MUfTRW5ITVJ?
BFTC-909 NWrt[4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;HOZlKSzVyPUeuNFA3PDFizszN MYfTRW5ITVJ?
NCI-SNU-5 NH3WfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVNXVzUUN3ME23MlAzOTV7IN88US=> MoP2V2FPT0WU
TE-5 M1TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInpeWdKSzVyPUeuNFI5QDFizszN NH:wN3dUSU6JRWK=
SK-MES-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;OU5NKSzVyPUeuNFU1OjdizszN M{nHZ3NCVkeHUh?=
SHP-77 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PWOWlEPTB;Nz6xN|k2OiEQvF2= NGnCNYlUSU6JRWK=
NCI-H1623 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLWTWM2OD15LkG0NFczKM7:TR?= MmntV2FPT0WU
TE-11 NVn5TWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTdwMUWxPFQh|ryP M1G2bnNCVkeHUh?=
EKVX MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\J[2lEPTB;Nz6xPVI3PyEQvF2= MmnZV2FPT0WU
OVCAR-3 NWS2cGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK2Nm9KSzVyPUeuNlEyOzNizszN MX3TRW5ITVJ?
C3A NU\RdGh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwM{S1NkDPxE1? NXO1S5l{W0GQR1XS
CFPAC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKzZW5oUUN3ME23MlM3OjJ{IN88US=> NI\KTHpUSU6JRWK=
MG-63 NFvFb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nBPWlEPTB;Nz60NVg1QSEQvF2= M{PNVXNCVkeHUh?=
KYSE-140 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13mZWlEPTB;Nz60OFA3OSEQvF2= MmfGV2FPT0WU
MPP-89 NYXT[ZBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfLelR[UUN3ME23MlU6PzJ7IN88US=> MknqV2FPT0WU
COLO-824 NFjlVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:0bZIzUUN3ME23MlczQDZ|IN88US=> MYnTRW5ITVJ?
SiHa MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTdwOEO3NFch|ryP M4S3bXNCVkeHUh?=
SNU-387 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzUTWM2OD15Lki1N|Q4KM7:TR?= Mn;OV2FPT0WU
A172 NWLPOmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjWcHpKSzVyPUeuPFYyPzJizszN MY\TRW5ITVJ?
COLO-680N Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTdwOUG3N{DPxE1? NYD5W3czW0GQR1XS
HCC1395 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;nTWM2OD16LkC1OFUzKM7:TR?= NWnld4xqW0GQR1XS
NCI-H28 M4TmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfPTWM2OD16LkC1PVY{KM7:TR?= NIT5Xo9USU6JRWK=
LC-2-ad MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX23Xo9{UUN3ME24MlIyQTN5IN88US=> MmPYV2FPT0WU
S-117 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LkUGlEPTB;OD6yOVM2OyEQvF2= M{LwSnNCVkeHUh?=
NCI-H1838 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS5UWh{UUN3ME24MlI2PzhzIN88US=> MkfRV2FPT0WU
PANC-10-05 NGDTSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HpOmlEPTB;OD6zO|A1PyEQvF2= MV3TRW5ITVJ?
KALS-1 NHnLNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjiZY9FUUN3ME24MlUxQTJ6IN88US=> MnjFV2FPT0WU
LS-1034 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLNO4tTUUN3ME24MlU4PDN5IN88US=> M17rdnNCVkeHUh?=
TGBC1TKB NETOT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NdIlKSzVyPUiuO|M2OzVizszN M13jWXNCVkeHUh?=
OE19 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jPZmlEPTB;OD63OlI3OiEQvF2= NHPWRodUSU6JRWK=
D-502MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D1XWlEPTB;OD63Olk6PCEQvF2= MVHTRW5ITVJ?
JEG-3 M{HMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSwcmVKSzVyPUiuO|g3OThizszN NWGwUIFrW0GQR1XS
DBTRG-05MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRThwOEe1OlUh|ryP NV;xUItnW0GQR1XS
ME-180 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLtTWM2OD17LkC2O|I2KM7:TR?= NVnJOJg{W0GQR1XS
NCI-H1573 M3HY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD17LkGwOVMzKM7:TR?= MUjTRW5ITVJ?
HCC2998 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\MSmlEPTB;OT6xN|Y5OSEQvF2= MUXTRW5ITVJ?
ACHN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTlwMkS5O|Uh|ryP NI[zT4xUSU6JRWK=
D-392MG NEjMS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwMkW3NVUh|ryP MmXWV2FPT0WU
no-11 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjHc3VMUUN3ME25MlI3ODJ6IN88US=> NXLO[pk{W0GQR1XS
KLE MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrlVWRKSzVyPUmuN|IzOzJizszN M{jRV3NCVkeHUh?=
Calu-6 NUDuXmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3rUW02UUN3ME25MlM4PTJ6IN88US=> NGCySW9USU6JRWK=
LB831-BLC M2rFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\2ZlZ2UUN3ME25MlQ2OTdzIN88US=> NF3se4hUSU6JRWK=
SW684 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHiTWM2OD17LkS2NVE3KM7:TR?= M3PNbnNCVkeHUh?=
SH-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rZXGlEPTB;OT60PVM3PCEQvF2= MlfjV2FPT0WU
IST-MES1 M3;CeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTlwNUG2OFQh|ryP MmXtV2FPT0WU
Saos-2 M2nDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPuTWM2OD17LkWyNVk2KM7:TR?= NV[wSGxsW0GQR1XS
NCI-H2087 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu3VGRKSzVyPUmuOlc{PTJizszN MULTRW5ITVJ?
SCC-9 M37ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jpVmlEPTB;OT63NVgyPiEQvF2= NYPqO2FnW0GQR1XS
MFE-280 M3zsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHriRldKSzVyPUmuO|I4QDVizszN MnnQV2FPT0WU
BEN M4HLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[5cWlEPTB;OT64NlE2QSEQvF2= NIDYOHhUSU6JRWK=
CP50-MEL-B M{LTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17UeGlEPTB;OT65NlQ{OiEQvF2= NGrIcWhUSU6JRWK=
SK-MEL-28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD1zMD6wNVk{KM7:TR?= NW\pd2E3W0GQR1XS
NCI-H2452 NUWyc|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2xTWM2OD1zMD6xOkDPxE1? M1;LOXNCVkeHUh?=
NCI-H1395 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml76TWM2OD1zMD6xO|gh|ryP MV\TRW5ITVJ?
NCI-H2052 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfJTWM2OD1zMD6xPFgzKM7:TR?= NEjCc21USU6JRWK=
A375 NFHmOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3ZWlEPTB;MUCuNlQ2OiEQvF2= MkTmV2FPT0WU
HCC38 NF;XRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nESGlEPTB;MUCuN|IzKM7:TR?= M4GxdXNCVkeHUh?=
LK-2 NVHHXlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnQ[IQ6UUN3ME2xNE41OjB6IN88US=> M4PiSHNCVkeHUh?=
SF126 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzzTWM2OD1zMD60O|I4KM7:TR?= Mm\EV2FPT0WU
SK-MEL-1 M2rBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzTTWM2OD1zMD63PFM5KM7:TR?= M1zldXNCVkeHUh?=
ACN NIHjNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPuWXJqUUN3ME2xNE45Pjd7IN88US=> NV7KeXk5W0GQR1XS
BB30-HNC NGrOZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFyLki3NVEh|ryP MWPTRW5ITVJ?
NCI-H747 NVXLNZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HoOWlEPTB;MUCuPFc1PiEQvF2= Mn73V2FPT0WU
KYSE-150 NG\IV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPne3RKSzVyPUGxMlA{QDdizszN MYrTRW5ITVJ?
D-247MG MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qyZmlEPTB;MUGuNVAxQSEQvF2= MX3TRW5ITVJ?
BxPC-3 NUjwUGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWyTWM2OD1zMT6zO|Q4KM7:TR?= NF7wRplUSU6JRWK=
SK-MEL-30 NYiwcpVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHmb5pKSzVyPUGxMlQxPzlizszN MX7TRW5ITVJ?
CAS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFzLkSxNFkh|ryP M1LVVnNCVkeHUh?=
no-10 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrLbGxKSzVyPUGyMlEzOTdizszN NGTJNmJUSU6JRWK=
NCI-H2405 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfPTo9[UUN3ME2xNk4zODN4IN88US=> NYrwNVRKW0GQR1XS
KGN NXu5d|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF{LkK5NFEh|ryP MXjTRW5ITVJ?
BB49-HNC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13IeWlEPTB;MUKuN|k2PiEQvF2= NF:ybGRUSU6JRWK=
NCI-H1693 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTpflVzUUN3ME2xNk42QDF4IN88US=> NEXWOYtUSU6JRWK=
RO82-W-1 MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXHSnRKSzVyPUGzMlA3PDlizszN MUPTRW5ITVJ?
CAL-85-1 NWPuZWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXBPJdKSzVyPUGzMlQ{QTlizszN MmPsV2FPT0WU
H-EMC-SS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfBO45KSzVyPUGzMlkyODRizszN NWLwRnJHW0GQR1XS
SW1783 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHixU4tKSzVyPUG0MlI{QTFizszN MoLmV2FPT0WU
LB771-HNC NGDKVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF2LkSxPUDPxE1? MnzGV2FPT0WU
HCC70 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUd2lEPTB;MUSuOFI{OyEQvF2= Ml\EV2FPT0WU
KNS-81-FD NYHJUphUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjVe4p7UUN3ME2xOE44ODR3IN88US=> M33PPHNCVkeHUh?=
KYSE-520 M2Ltdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3eycmlEPTB;MUSuPVI4KM7:TR?= M1PjOXNCVkeHUh?=
TGBC24TKB NXe2bYV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLVZWMzUUN3ME2xOE46PTN7IN88US=> Mmi5V2FPT0WU
SNB75 NVrHW4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17DTmlEPTB;MUWuNFczQSEQvF2= NHfINYlUSU6JRWK=
SW872 NFmxSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6W3RmUUN3ME2xOU4zOjF6IN88US=> MWrTRW5ITVJ?
U031 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zOUmlEPTB;MUWuPFAzQCEQvF2= NHzxb5ZUSU6JRWK=
ChaGo-K-1 NX7qS|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHh[JJKSzVyPUG1Mlg{PTlizszN MoTtV2FPT0WU
NCI-H441 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LpRmlEPTB;MU[uNFA{QSEQvF2= NI\WSVFUSU6JRWK=
TE-12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF4LkG4O|Mh|ryP MkHYV2FPT0WU
NCI-H1755 NIHHdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF4LkW3N{DPxE1? MonPV2FPT0WU
KNS-42 NHHsWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzlWJpKSzVyPUG2MlY2QDlizszN NHPIO5pUSU6JRWK=
SK-PN-DW Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqyeGhyUUN3ME2xO{41OjBzIN88US=> Mm[xV2FPT0WU
NCI-H226 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfhTXhyUUN3ME2xO{46OzR3IN88US=> M1rCOXNCVkeHUh?=
K-562 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33kVGlEPTB;MUiuOlMyPyEQvF2= MYHTRW5ITVJ?
A388 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF7LkCzNFMh|ryP MkWxV2FPT0WU
ZR-75-30 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJb5J1UUN3ME2xPU4xQTZ6IN88US=> NHLyU45USU6JRWK=
LU-135 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvFZ|NmUUN3ME2xPU4zPjN4IN88US=> MYnTRW5ITVJ?
NCI-H2029 NYOyfZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PhRmlEPTB;MUmuOlAzOSEQvF2= NV7HR5M5W0GQR1XS
HT-1197 NGjHfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DzcGlEPTB;MUmuPVIzPyEQvF2= NUHOfpFmW0GQR1XS
IGR-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJyLkOxNVch|ryP NFr0cHpUSU6JRWK=
U-87-MG MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH6OWNKSzVyPUKwMlY1OTNizszN NXnxcplxW0GQR1XS
NCI-H1304 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf4W|BnUUN3ME2yNE44PTBzIN88US=> NUDHT3JtW0GQR1XS
RCC10RGB NFjPfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0PY9KSzVyPUKxMlI5OjlizszN M{j6VnNCVkeHUh?=
NCI-H520 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\OUoVEUUN3ME2yNk44PjFzIN88US=> NHTJd4xUSU6JRWK=
SK-LU-1 NUfpd4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ|LkC3NVgh|ryP MUHTRW5ITVJ?
UACC-893 M13MOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvw[IU2UUN3ME2yN{4yODN6IN88US=> NYDLfHo1W0GQR1XS
NCI-H2347 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ|LkK2O|Qh|ryP NF\kfGtUSU6JRWK=
U-118-MG MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ|LkeyNVch|ryP M2rHNnNCVkeHUh?=
NCI-H596 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nIPGlEPTB;MkOuPVA2PSEQvF2= NYPhVllTW0GQR1XS
MZ1-PC M2q4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkRVFKSzVyPUK0MlY4PTlizszN MkjFV2FPT0WU
SW1417 NGKwWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzmTWM2OD1{NT6yOFk5KM7:TR?= NYD3V3ZmW0GQR1XS
NCI-H82 M3vGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ4LkSyPFgh|ryP NXn2b2FNW0GQR1XS
COLO-678 M2e4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PaeGlEPTB;MkeuOFkyQSEQvF2= NVL0ZZVuW0GQR1XS
KURAMOCHI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvpTWM2OD1{OD6xNlYh|ryP MVnTRW5ITVJ?
NCI-H1650 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrYTWM2OD1|MD6xPVI1KM7:TR?= Mk\IV2FPT0WU
HCC1954 NIPCfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr2OGFKSzVyPUOxMlM3PjZizszN MXPTRW5ITVJ?
GAK NYH2WHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvDTWM2OD1|Mj6yOlE3KM7:TR?= MUjTRW5ITVJ?
YAPC M{n3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfVRoRMUUN3ME2zN{44PjR6IN88US=> MUHTRW5ITVJ?
NCI-H2228 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7QN4k3UUN3ME2zOE4{PjB3IN88US=> MXfTRW5ITVJ?
VMRC-RCZ NXP3W3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN4LkOwNlIh|ryP M4DXbHNCVkeHUh?=
NMC-G1 NYPvcYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmzfVVKSzVyPUO3MlA2OjlizszN MV\TRW5ITVJ?
D-336MG MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv1e2JKSzVyPUSxMlg1PDJizszN NHn5clNUSU6JRWK=
UACC-62 M1T5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjJbIpKSzVyPUSyMlU2ODVizszN M3TwZXNCVkeHUh?=
C-33-A M4fvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnZTWM2OD12NT6zNlU3KM7:TR?= NFjmR4RUSU6JRWK=
HCC1937 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzUnBKSzVyPUS3MlE6PThizszN NUnEbWVqW0GQR1XS
HDLM-2 NHXONINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD12Nz6yNlg4KM7:TR?= MlPYV2FPT0WU
NCI-H727 NETWNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zWGlEPTB;NEeuNlQ2OSEQvF2= MWjTRW5ITVJ?
NY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkXI9{UUN3ME20PU4{QTB6IN88US=> MX7TRW5ITVJ?
NCI-H2291 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR7LkizNFEh|ryP NEj6VFJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research:

[2]

+ Expand
  • Cell lines: LNCaP, PC-3, and TSU-Pr1
  • Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
  • Incubation Time: 1, 2, 3 and 4 days
  • Method:

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • Formulation: Dissolved in DMSO
  • Dosages: ~100 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 264.3
Formula

C14H20N2O3

CAS No. 149647-78-9
Storage powder
in solvent
Synonyms SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01281176 Active not recruiting Adult Solid Neoplasm National Cancer Institute (NCI) February 9 2011 Phase 1
NCT01189266 Active not recruiting Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Brain Stem Glioma|Childhood Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligoastrocytoma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Gliosarcoma National Cancer Institute (NCI) August 9 2010 Phase 1|Phase 2
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT03198559 Suspended HIV Infections The Peter Doherty Institute for Infection and Immunity|Merck Sharp & Dohme Corp.|The Alfred|University of Melbourne August 8 2017 Phase 1|Phase 2
NCT02538510 Active not recruiting Head and Neck Squamous Cell Carcinoma|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharynx Carcinoma|Recurrent Salivary Gland Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage III Major Salivary Gland Carcinoma|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage III Nasopharyngeal Carcinoma|Stage IV Nasopharyngeal Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Major Salivary Gland Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma University of Washington|National Cancer Institute (NCI) October 8 2015 Phase 1|Phase 2
NCT01983969 Completed Advanced Cancers|Lymphoma M.D. Anderson Cancer Center November 7 2013 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • Answer:

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) supplier | purchase Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) manufacturer | order Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID